

Heterogeneity in human hippocampal CaMKII transcripts reveals allosteric hub-dependent regulation

Roman Sloutsky^{1‡}, Noelle Dziejczak^{1,2‡}, Matthew J. Dunn¹, Rachel M. Bates¹, Ana P. Torres-Ocampo^{1,2}, Sivakumar Boopathy³, Brendan Page¹, John G. Weeks¹, Luke H. Chao^{3*}, Margaret M. Stratton^{1*}

Department of Biochemistry and Molecular Biology¹, Molecular and Cellular Biology Graduate Program², University of Massachusetts, Amherst, United States, Department of Molecular Biology³, Massachusetts General Hospital and Department of Genetics Harvard Medical School, Boston MA

*To whom correspondence should be addressed: mstratton@umass.edu and chao@molbio.mgh.harvard.edu

‡These authors contributed equally

One Sentence Summary

CaMKII is a well-conserved protein that is essential for learning and memory. When CaMKII is mutated in a mouse, this mouse has difficulty learning and remembering how to get through a maze. The hippocampus is the part of the brain required for memory. Here, we used a specific experiment to determine every type of CaMKII that is in a human hippocampus. We found 70 different types and then asked how these differences affect CaMKII function. These data provide evidence that an assembly domain of CaMKII plays an unexpected role regulating its activity. This new finding helps us better understand endogenous CaMKII in the brain and provides a new mechanism for modulating CaMKII activity.

Abstract

Ca²⁺-calmodulin dependent protein kinase II (CaMKII) plays a central role in Ca²⁺ signaling throughout the body. Specifically in the hippocampus, CaMKII is required for learning and memory. CaMKII is encoded by four highly conserved genes in vertebrates: α , β , γ , and δ . All CaMKIIs are comprised of a kinase domain, regulatory segment, variable linker region, and hub domain responsible for oligomerization. The four genes differ primarily in linker length and composition due to extensive alternative splicing. Here, we unambiguously report the heterogeneity of CaMKII transcripts in 3 complex samples of human hippocampus using Illumina sequencing. Our results show that hippocampal cells contain a diverse collection of 70 CaMKII transcripts from all four CaMKII genes. We characterized the Ca²⁺/CaM sensitivity of hippocampal CaMKII variants spanning a broad range of linker lengths and compositions. We demonstrate that the effect of the variable linker on Ca²⁺/CaM sensitivity is conditional on kinase and hub domains. Moreover, we reveal a novel role for the hub domain as an allosteric regulator of kinase activity, which may provide a new pharmacological target for modulating CaMKII activity. Using small angle X-ray scattering and single-particle electron cryo-microscopy, we present evidence for extensive interaction between the kinase and the hub domain, even in the presence of a 30-residue linker. Taken together, we propose that Ca²⁺/CaM sensitivity in CaMKII is gene-dependent and includes significant contributions from the hub. Our sequencing approach combined with biochemistry provides new insights into understanding the complex pool of endogenous CaMKII.

Introduction

Ca²⁺/calmodulin dependent protein kinase II (CaMKII) is a crucial oligomeric Ser/Thr kinase in long-term memory formation (1) as well as egg activation in fertilization (2,3), and cardiac pacemaking (4). CaMKII is expressed throughout the human body, which facilitates its role in these disparate functions. There are four human genes that encode CaMKII: CaMKII α and β (predominantly in brain), CaMKII δ (predominant in heart) and CaMKII γ (multiple organ systems, including egg and sperm) (5-7). In all four genes, each CaMKII subunit is comprised of a kinase domain, regulatory segment, variable linker region, and a hub domain (Fig. 1A). The kinase and hub domains are highly conserved across the four genes, with minimum 90% and 75% pairwise identity, respectively. The linker that connects the kinase and hub domains is highly variable in length and composition due to alternative splicing. Herein, we focus on CaMKII in the hippocampus, the primary memory center in the brain (8). CaMKII is the most abundant enzyme in neuronal dendrites and has been implicated functionally in memory (1). Transgenic mice deficient in neuronal CaMKII have limited long-term memory and display specific learning impairments (9,10). More specifically, mice with mutations at critical phosphorylation sites in CaMKII display defects in higher order memory and adaptive learning (11).

The structure and function of both the kinase and hub domains of CaMKII have been well studied. Kinase activity is regulated by the autoinhibitory regulatory segment, which blocks the substrate-binding site in the absence of Ca²⁺ (12). When Ca²⁺ levels rise, Ca²⁺ bound calmodulin (Ca²⁺/CaM) competitively binds to the regulatory segment and relieves inhibition by exposing the substrate-binding site (Fig. 1B) (13). The regulatory segment also contains three sites of

autophosphorylation: Thr²⁸⁶, Thr³⁰⁵, Thr³⁰⁶ (following CaMKII α numbering) (14). Notably, phosphorylation at Thr²⁸⁶ results in autonomous activation, or, sustained activity in the absence of Ca²⁺ (15). The hub domain oligomerizes the holoenzyme into both dodecameric and tetradecameric assemblies (Fig. 1C) (16-18).

The variable linker region has been difficult to study for several reasons. The sequence of the linker is predicted to be disordered. It is likely for this reason that high-resolution structures of the CaMKII holoenzyme including the linker region have not been solved. Indeed, the only atomic resolution structure of a CaMKII holoenzyme is one in which the variable linker is completely deleted (19). In this structure, the regulatory segment makes extensive contacts with the hub domain, thereby completely sequestering the CaM binding segment from Ca²⁺/CaM in this compact conformation. This structure, combined with biochemical data discussed below, led to the hypothesis that linker length tunes the autoinhibition within the holoenzyme by either stabilizing a compact conformation (short linker forms) or populating an extended conformation where the CaM binding segment is more accessible (longer linker forms).

The variable linker also varies in composition between the four CaMKII genes. Further complexity is generated by alternative splicing of up to 9 exons (exons 13-21) in each linker, creating a total of more than 50 variants possibly expressed from four genes (Fig. 2A). The combination of high identity within the conserved kinase and hub domains and high variability in the linker region makes it difficult to specifically identify splice variants of the CaMKII paralogs in cellular experiments.

There have been many studies that outline specific roles for exons in the variable linker region, which provide some clues as to why exons may be spliced in or out. Exon 15, which is encoded in all genes with the exception of CaMKII β has been documented to contain a nuclear localization sequence (NLS) (20-22). This NLS (KKRK) is a common motif identified as a sufficient sequence to achieve nuclear localization (23). Exon 13, which is encoded in CaMKII β and γ , but not α or δ , mediates an important interaction with F-actin (24,25). In dendritic spines, CaMKII interacting with actin is crucial for the maintenance of spine structure during long-term potentiation (26). Perhaps the most dramatic form of alternative splicing results in the formation of alpha CaMKII associated protein (alpha KAP) where CaMKII α is spliced to a form that includes only the hub domain (27). This splice variant plays an important role in membrane anchoring using its hydrophobic N-terminal domain (28). Finally, it was shown that alternative splicing within the hub might regulate oligomerization (5). Roles for the remaining exons have yet to be delineated.

In addition to roles assigned to specific exons, the variable linker region has also been shown to play a critical role in CaMKII activation. A standard metric for CaMKII activity is the concentration of Ca²⁺/CaM required for half-maximal activation (EC₅₀ value) (19,29). It has also been clearly shown that CaMKII activation is cooperative (29). In regard to linker length, a CaMKII α variant with a 30-residue linker has been shown to require substantially less Ca²⁺/CaM to achieve maximal activity compared to a CaMKII α variant with a 0-residue linker (19). This general trend also holds in comparing a long linker CaMKII β variant to a short linker CaMKII α variant (30).

Here, we address the gaps in knowledge in three major areas: 1) which specific CaMKII splice variants are expressed in human hippocampal cells, 2) how splicing affects CaMKII activation, and 3) structural analysis of an autoinhibited CaMKII holoenzyme with a 30-residue linker.

Results

The exon architecture is conserved between CaMKII paralogs

The four genes encoding CaMKII in humans share a high degree of homology. Using the Neighbor Joining method (31,32), we created reconstructions of the kinase and hub domain divergence for the four human CaMKII genes rooted with *D. melanogaster* CaMKII kinase and hub outgroups (Fig. 1D). Because of the clear one-to-one correspondence of exons across genes, we employed a common exon numbering system (Fig. 2A). Herein, we implement a new naming scheme for CaMKII variants based on ¹gene identity and ²incorporated exons. Moving forward, we propose this is the simplest way to efficiently catalog current CaMKII variants and include new variants as they are discovered.

Deep sequencing reveals at least 70 CaMKII transcript variants in human hippocampus

We carried out targeted deep sequencing of hippocampal CaMKII transcripts from three separate human donors (82, 26, and 66 year-old males) without neurological or neuropsychiatric diagnoses. In order to identify all alternatively spliced CaMKII transcripts expressed in a human total RNA sample, these transcripts must be substantially enriched. Similar to earlier approaches (1,3,33-35), we reverse-transcribed human hippocampal RNA to generate cDNA and then used gene-specific primer pairs to PCR-amplify variable regions of CaMKII transcripts (Fig. 2B).

Agarose gel separation of PCR amplicons followed by Sanger sequencing of excised gel bands was inadequate for detailed characterization of alternative CaMKII splicing, because many bands contained mixtures of variants (fig. S1). To circumvent this issue, we devised an Illumina next-generation sequencing approach. Given the locations at which CaMKII transcripts are variably spliced and the maximal lengths of variable regions when all optional exons are incorporated, strategic placement of a primer pair facilitates PCR-based construction of Illumina sequencing libraries such that 251bp paired-end sequencing allowed unambiguous identification of virtually all possible CaMKII transcripts from all four genes (Fig. 2B, blue/green primer pair). Compared to traditional whole-transcriptome Illumina RNA-Seq library preparation, this approach emphasizes sensitivity of unambiguous variant detection over accuracy in quantification of relative transcript abundance, due to the greater potential for amplification bias resulting from additional PCR cycles. Therefore, we make no claims with respect to transcript abundance beyond classifying transcripts into several detection level categories based on the number of reads mapped to each transcript. However, spurious detection of transcripts is extremely unlikely, since we applied a stringent similarity cutoff of a minimum of 10 reads mapping to each transcript (see Materials and Methods).

We performed this experiment with three separate donor samples of human hippocampal tissue. We detected a surprisingly large number of distinct transcript variants (Fig. 2C, Tables S1-S16, data file S1), including 3 CaMKII α variants and over 15 each of CaMKII β , CaMKII γ , and CaMKII δ . In addition to variants previously annotated in genomic databases (NCBI Consensus CDS collection, NCBI GenBank, Ensembl), we also identified numerous previously unobserved variants of each gene, which we refer to as ‘unreported’ in this manuscript. One unreported

variant of note was the CaMKII α transcript including no optional linker exons (0 aa linker). This is significant because the crystal structure of CaMKII α no-linker variant is the only available high resolution structure of full length CaMKII (pdb: 3SOA (19)), but this variant was previously not known to be biologically relevant.

Nearly every identified transcript incorporating optional linker exons contained exons 14 and 18, suggesting these two exons constitute a “core” linker predating the divergence of the four genes. Assuming the core is mandatory if any other linker exons are to be spliced in, we observed a large fraction of allowable linker sequences for each gene. CaMKII β variants incorporating proline-rich exons 19, 20, or 21 and CaMKII γ variants incorporating F-actin-interacting exon 13, which were not detected in our experiment, are two notable exceptions.

We assessed the reproducibility of this experiment with two replicates of sample preparation and sequencing for Donor 1, the highest quality tissue and RNA sample (Fig. 2C, Tables S1-S4). For these technical replicates, 99% of reads mapped to the same collection of variants. Not surprisingly, variants on the edge of detection (cumulatively mapping to 1% of reads) differed between the replicates (Tables S2, S6, S10, and S14). However, there was too much variability between the replicates to precisely quantify detection levels of variants and confidently order them based on detection level (Materials and Methods, Tables S17-S19). Instead we bin variants into several detection-level categories.

Expressed variants were also quite consistent across donors, with at least 97.5% of all reads from each donor mapped to a collection of variants detected in all three donors (Tables S1-S16). Most,

but not all, variants fell into the same broad expression category across all donors. Accordingly, we designated variants as ‘consistent’ and ‘inconsistent’ (Tables S1, S5, S9, S13). Large differences in detection levels between donors observed for inconsistent variants may reflect underlying physiological differences between donors.

The variable linker affects activation of CaMKII α , but not CaMKII β

We focused on the activation properties of CaMKII α and β variants because of their well-documented involvement in learning and memory (9,11). First, we determined the EC₅₀ values for Ca²⁺/CaM activation of all three CaMKII α variants sequenced from human hippocampus. For all EC₅₀ measurements, the curve fit is shown for simplicity (Fig. 3), and fits with all data points used are shown (fig. S2). For brevity we refer to variants by linker length: α -41 (α 14,15,18 in Fig. 2C), α -30 (α 14,18), and α -0 (α -no-linker). In agreement with previous experiments comparing α -30 to α -0 (19), we also observed a large right-shift in the EC₅₀ value (from 24 nM to 313 nM, respectively, Fig. 3A). CaMKII α -41 (EC₅₀ = 25 nM, Fig. 3A) did not show a significant difference compared to α -30.

Next, we examined CaMKII β variants with the broadest possible range of variable linker lengths: previously annotated and detected variants β -93, β -69, β -68, β -54, β -30, and β -0, as well as the annotated, but undetected, variant β -217 (Fig. 3B). Quite surprisingly, we observed no major differences in EC₅₀ across the entire range of linker lengths, with EC₅₀ of all β variants falling in the narrow range between 14-31 nM. This result showed that the variable linker does not tune activation the same way in different CaMKII genes. The Hill coefficients (n_H) from these measurements of CaMKII α and β variants were all quite similar, ranging from 1.5 to 2.5, which

was consistent with previous measurements (19). Of note, the cooperativity in CaMKII β variants were consistently higher compared to CaMKII α , but did not correlate with EC₅₀ value differences.

We observed a 15-fold difference in the EC₅₀ for Ca²⁺/CaM between α -0 and β -0 (313 nM vs 21 nM). The difference in activation properties of these two variants may be attributed to sequence differences outside of the variable linker: in the kinase domain, the hub domain, or a combination of the two. In fact, the only CaMKII β variant we tested with an EC₅₀ outside of the narrow range around 20 nM was the novel variant β -93-short-hub, which is slightly right-shifted from the other CaMKII β variants (Fig. 3B). The only difference between β -93 (EC₅₀ = 25 nM) and β -93-short-hub (EC₅₀ = 43 nM) are 26 residues missing in the hub domain, indicating that hub alone may affect activation properties. These results motivated our next experiments.

Hub identity plays a regulatory role in holoenzyme activation

We directly assessed the regulatory contribution of the kinase and hub domains of CaMKII α and β (90% and 77% identity, respectively). To do this, we created two chimeras with 0aa linkers. The first chimera was the CaMKII α kinase domain and regulatory segment fused to the CaMKII β hub domain, and the second chimera was the CaMKII β kinase domain and regulatory segment fused to the CaMKII α hub domain. The EC₅₀ value of the β kinase/ α hub chimera was substantially right-shifted compared to that of the α kinase/ β hub chimera (Fig. 3C). Both CaMKII β -0 and the chimera with the β hub had roughly the same EC₅₀ (24 nM and 21 nM, respectively). On the other hand, CaMKII α -0 and the chimera with the α hub were both right-shifted. However, the EC₅₀ of the chimera was still 3-fold lower than the EC₅₀ of wild type

CaMKII α -0: 102 nM vs 313 nM. This suggested that the role of the hub domain in determining activation properties was dominant with respect to the kinase domain, with no contribution from the kinase in the context of β hub, but a significant contribution in the context of α hub.

Activation properties track with evolutionary divergence

We compared the divergence of human CaMKII kinase and hub domains using the corresponding domains from the single CaMKII gene in fly as outgroup to root the trees (Fig. 1D). The kinase and hub trees have consistent topologies, in which the common ancestor of CaMKII α and δ diverged from the common ancestor of β and γ . However, while the four kinase domains diverged in nearly a star topology (the segments separating the α/δ and β/γ ancestors from their common ancestor are much shorter than any other segment), hub divergence was not nearly as uniform. CaMKII α and δ are much more diverged from each other and from β/γ . CaMKII β and γ hubs have diverged by far the least, with the fewest substitutions between them. Based on this similarity, and the apparent involvement of the hub domain in activation, we hypothesized that γ -0 would behave similarly to β -0. We measured activation of γ -0 and δ -0 (Fig. 3D), confirming our hypothesis (γ -0: $EC_{50} = 28$ nM). Consistent with the order in which α , β/γ , and δ split, as well as with the greater degree of divergence between α and δ hubs, δ -0 required an intermediate amount of Ca^{2+}/CaM for activation ($EC_{50} = 167$ nM): roughly 7-fold higher than β -0, but 2-fold lower than α -0.

Insight into the structural mechanism of activity regulation

The striking difference we observed in the activation of CaMKII α -0 compared to CaMKII β -0 (EC_{50} = 313 nM and 21 nM, respectively) led us to investigate whether there was a structural explanation. The crystal structure of CaMKII α -0 shows a compact conformation with a radius of gyration (R_g) of 61 Å as determined using small angle X-ray scattering (SAXS) (19). We performed SAXS measurements to compare the overall shape of CaMKII α -0 and CaMKII β -0 in the unactivated conformation (without addition of Ca^{2+} /CaM). Guinier and pair distribution analyses revealed a significant difference in the R_g and D_{max} of CaMKII α -0 (~59 Å and 155 Å, in line with previous data (19)) compared to CaMKII β -0 (~66.4 Å and 250 Å) (fig S3). These results showed that CaMKII α -0 is in a more compact conformation than CaMKII β -0.

Our current understanding of the CaMKII holoenzyme state (compact versus extended) has emerged from a combination of negative stain EM, SAXS, and X-ray crystallography, as reviewed by (31). The central hub is consistently observed as a dodecameric or tetradecameric assembly. The kinase domains have been observed in multiple conformations, including above and below the hub domain plane in EM studies (32), in compact positions docked against the hub in an X-ray crystal structure (19), or in the same plane as the central hub at extended positions, from EM and SAXS modeling (33,34). Another negative stain EM study of a CaMKII α -30 construct showed the kinases adopting positions at extended distances from the central hub (35). A general challenge for 3D EM reconstructions of CaMKII has been the strong preferred orientation of the sample under both cryo and negative stain conditions. In addition, the average size of negative stain particles and the linker distances present in CaMKII isoforms have

motivated careful comparison of negative stain and cryo-conditions when interpreting kinase domain position (32).

To revisit questions surrounding the CaMKII holoenzyme conformational state, we analyzed samples of CaMKII α -30 using single particle cryo-EM. 2D class averages of the sample, frozen at 0.5-1 mg/ml, showed clearly distinguishable 6-fold and 7-fold versions of the central hub with visible secondary structure elements (Fig. 5A). Obvious side views were visible in the 2D classes, in contrast with previous negative stain analyses (Fig. 5B) (17,35,36). 2D classes also showed additional, less ordered density, proximal of the hub (presumably from the kinase domains) (Fig. 5C, D). This density was still present when the mask diameter was expanded during 2D classification (Fig. 5E). No additional ordered density, at more extended positions, appeared to be excluded due to masking. In top views of 6- and 7-fold hub assemblies, additional kinase domain density was observed as a strong signal positioned between hub subunits (Fig. 5C), and was observed in side-views above and below the mid plane of the hub (Fig. 5D, E).

We generated initial models using Relion initial model, and classified the full particle set, all without any assumptions of symmetry (see Materials and Methods for details). Both 6-fold and 7-fold hub domains (without any ordered kinase domains) emerged during 3D classification. Ordered density of the kinase domains appeared in two final classes. The first class, which we refer to as Class A, was refined to 4.8 Å resolution (as evaluated by gold standard FSC (Fourier Shell Correlation) criterion). In Class A we observed one ordered kinase domain, docked against a 6-fold hub in a position with the beta-clip engaged with the hub, as seen in the crystal structure of CaMKII α -0 (pdb: 3SOA) (Fig. 5). A second class (Class B) was refined to 6.6 Å resolution.

Class B showed one kinase domain interacting with a 6-fold hub in a new orientation. In Class B, the kinase C-lobe (helices: α EF and α G) engaged a loop in the hub domain (W373-P379), and the N-lobe was in a position closer to the hub mid-plane. In both reconstructions, the electron density (with recognizable secondary structure elements) was unambiguous for positioning the kinase domain. Both Class A and B exhibited preference for top views, however these data showed angular distributions which allowed 3D reconstruction (fig. S4). Similar docked states as Class A and B were seen with 7-fold hubs. Enforcing D6 symmetry during refinement of the Class A or Class B particles resulted in reconstructions with a recognizable central hub, but loss of recognizable kinase density.

Discussion

We unambiguously identified at least 70 distinctly spliced CaMKII transcripts present in three individual human hippocampal samples using Illumina sequencing. It is important to note that excised hippocampal tissue samples are necessarily comprised of multiple cell types from the hippocampus, including neurons, glia, interneurons, etc. Therefore, the transcripts we report here are derived from this mixture of cell types, not from excitatory neurons alone. From our experiment, it is impossible to tell which transcripts are co-expressed specifically in excitatory neurons or any other cell type. Addressing this important question requires precise extraction of individual neurons from the hippocampus followed by single-cell transcript sequencing. The alternative, culturing neurons outside of brain tissue, disrupts numerous *in vivo* cell-cell interactions, including synapses, quite possibly leading to non-physiological changes in CaMKII transcription and splicing.

Using the sequences we obtained, and others previously annotated from various tissues, we examined the differences in kinase activity regulation between CaMKII genes and splice variants. We discovered that, while CaMKII α regulation is dependent on the variable linker region, CaMKII β regulation is not. Further, we now show a role for the hub domain in the regulation of CaMKII activation by Ca²⁺/CaM. Our data provide important insights into the heterogeneity of CaMKII transcripts in a human tissue and uncover a new role for the hub domain in regulating CaMKII activity through an allosteric mechanism. This finding opens a new window to allosteric control of CaMKII activity through modulation of the hub domain.

We sequenced a large number of transcripts from all four CaMKII genes from 3 separate samples of human hippocampal tissue. Notably, CaMKII α produced a no-linker transcript (CaMKII α -0) that accounted for 0.5% - 25% of mapped reads. This sequence was previously crystallized to obtain the only full-length atomic resolution structure of CaMKII. Our data demonstrate the potential physiological relevance of the compact conformation observed in that structure (19). The sheer number of detected variants detected in the hippocampus (70 across the four CaMKII genes) suggests that a) either splicing is not tightly regulated at every exon, or b) there are complex mechanisms of regulation responsible for every transcript we detected. In either case, certain exons (proline-rich CaMKII β exons 19-21 and F-actin-interacting CaMKII γ exon 13) appear to be specifically suppressed in the hippocampus.

In terms of abundance of detected transcripts, systematic PCR bias is unlikely to be solely responsible for the roughly 1000-fold differences between the high- and trace-level detection categories of detected variants of CaMKII β , γ , and δ (Tables S1, S5, S9, S13). Physiological

differences in transcript copy number between variants likely contributed to these differences in detection level. Furthermore, given the overall consistency in variant detection between donors, the few instances of dramatic detection level differences may reflect genuine physiological differences between individuals.

We found that agarose gel separation of transcripts followed by Sanger sequencing of individual bands cannot resolve CaMKII variants from hippocampus, because sequencing traces from most bands clearly indicated a mixture of templates present in the sequenced sample. In many cases, careful analysis of the Sanger sequencing trace allowed us to identify at least two distinct splice variants (fig. S1). Therefore, it is difficult to interpret the presence or absence of an expected gel band as indicative of the presence or absence of a particular CaMKII transcript in a sample.

Since each Illumina read obtained by our approach reflects a single template molecule, it produces a more robust survey of the CaMKII transcripts. We suggest that this approach should be applied to other tissues to begin to catalog the diversity in CaMKII transcripts. We expect that in other tissues the identity and relative abundance of transcripts will vary from those we observed in the hippocampus. With this information in hand, we will certainly improve our understanding of the regulation of CaMKII alternative splicing, and ultimately be able to link this regulation to the Ca²⁺ signaling requirements within each tissue.

Our results comparing the EC₅₀ values between CaMKII α and β splice variants show that the regulation of CaMKII activation is gene-dependent and, specifically, affected by the sequence of hub domain. Our measurements characterize CaMKII activation at equilibrium Ca²⁺/CaM concentrations. CaMKII activity is also dependent on the frequency of Ca²⁺ spikes, which is how

Ca^{2+} is delivered to endogenous CaMKII in post-synaptic neuron (19,30,37). Future experiments will be needed to carefully dissect this kinetic contribution in activation of different splice variants. The variable linker in CaMKII α does play a role in regulating CaMKII α activity, which is consistent with previous work (19). We used cartoon holoenzymes illustrate the compact and extended autoinhibited states of CaMKII (Fig. 3), which correspond to lower and higher sensitivities to $\text{Ca}^{2+}/\text{CaM}$, respectively. For CaMKII α , these cartoons are based on a crystal structure (pdb: 3SOA) and SAXS measurements, respectively (19). Surprisingly, the variable linker in CaMKII β does not play a role in regulating CaMKII β activity. Our SAXS measurements directly comparing CaMKII α -0 and β -0 suggest that α -0 adopts a compact conformation whereas β -0 adopts a more extended conformation as evidenced by its larger R_g and D_{\max} (fig. S3). This data corroborates the trend that was previously observed comparing α -0 and α -30 where the more compact conformation is requires more $\text{Ca}^{2+}/\text{CaM}$ for activation (19), which is what we observe in our experiments as well.

Our results with CaMKII α and β chimeras provide evidence that the hub identity is a determinant of sensitivity to $\text{Ca}^{2+}/\text{CaM}$. We observed a large difference in activation of the CaMKII β kinase when it was fused to the CaMKII α hub domain. Substitutions between CaMKII α and β hub domain sequences are distributed quite uniformly throughout the domain (Fig. 4A). This led us to hypothesize that there is a dynamic component to this regulation. We turned to single particle cryo-EM to gain a better understanding of the structural mechanism of activity regulation.

Our cryo-EM data show that the kinase domains are in close physical contact with the hub, and suggest two specific sources for hub-dependent regulation observed in the chimera experiments.

These cryo-EM data clearly observe two conformations sampled by the kinase domain under frozen hydrated conditions. First, we observe the same docked conformation in single-particle cryo-EM reconstructions using CaMKII α -30 (Fig. 6A, Class A) that was observed in a crystal structure of CaMKII α -0 (19). The crystal structure shows a compact state of the holoenzyme where the kinase domain is docked onto the hub domain and the calmodulin binding segment is occluded. The conformation we observe in cryo-EM (Class A) suggests that with the holoenzyme in solution, kinase domains may sample a similar compact state, even in the presence of a 30-residue linker. Single amino acid substitutions from CaMKII α to β are not found at this docking interface, thereby confounding straightforward tests of this interface in hub-dependent regulation. Our cryo-EM analysis also revealed a new second, distinct docked state, Class B (Fig. 6B). In this reconstruction, the kinase domain is flipped relative to Class A, with the C-lobe oriented above the N-lobe, relative the hub. A loop in the hub domain mediating interaction is variable between CaMKII α and β (Fig. 4B, black box). In Class B, the regulatory segment is accessible for calmodulin binding, but there remains extensive contact between the kinase C-lobe and the hub, which may influence activation. These two cryo-EM reconstructions advance our understanding of holoenzyme architecture because they show that in a holoenzyme with a 30-residue linker the kinase domains make intimate contact with the hub, to the extent that two distinct cryo-EM reconstructions can be observed with specific docked conformations.

We note that in these reconstructions, only one kinase domain was sufficiently ordered to be resolved in the final reconstruction of a dodecamer. The final reconstructions for Class A and B were obtained with masks that excluded non-modeled density, as standard. Outside of this masked region was unaccounted density present above and below the midplane, as observed in

the 2D class averages (Fig. 5). This significant disordered density may reflect extensive transient interactions between the hub and kinase domains. The position of the unmodeled density is consistent with kinase domain positions along the surface of the hub, and incompatible with the extended positions proposed in the negative stain reconstructions (35). It will be interesting to investigate whether constructions like CaMKII α kinase/ β hub chimera show this kinase proximity to the hub or not. The 30-residue linker in CaMKII α -30 is predicted to be a disordered segment. This disordered linker allows the kinase domains many degrees of freedom. Locking the kinase into a docked conformation is likely to be entropically unfavorable and transient, making coincident docking statistically unlikely.

Our cryo-EM analysis shows two 3D reconstructions of CaMKII α -30 with different docked states in which the kinase domain makes direct contact with the hub. We speculate that these interactions may mediate autoinhibition or calmodulin-dependent activation. As the interactions we observe may vary depending on the identity of the CaMKII hub domain, they do not exclude other interactions, which may be uncovered when kinase domains are less likely to interact with the hub (34). With the rich diversity of splice variants described here, a given holoenzyme may have an entire set of regulatory interactions it can sample. Thoughtful future experiments will be needed to specifically distinguish the role of these dynamic interactions in holoenzyme activation, to more fully elucidate the intricate mechanistic details of a remarkably versatile enzyme.

Materials and Methods

Initial amplification of transcript variable regions

Two human total RNA samples and one human cDNA sample were commercially purchased from BioChain. The samples were derived from complete hippocampi of three human donors (donor 1: 82 year old male, donor 2: 26 year old male, donor 3: 66 year old male) without neurological or psychiatric diagnoses. BioChain advised that the tissue from donor 2 did not pass all internal histological quality controls, although the RNA derived from that tissue did pass all RNA quality controls. We detected many fewer low-expression variants (less than 1% of mapped reads) of CaMKII β , γ , and δ in the sample from donor 2, compared to donors 1 and 3. However, robustly expressed variants were highly consistent between all three donors (Tables S1-S16). This is consistent with non-specific partial degradation of RNA in the donor 2 sample. While low copy number transcripts fell below the threshold of detection due to partial degradation across all mRNAs, robustly expressed transcripts remained detectable, despite losing a fraction of their initial copy number.

cDNA was reverse-transcribed from donor 1 and donor 2 RNA samples using the ProtoScript II first strand cDNA synthesis kit (NEB #E6560) with oligo dT priming. Variable regions of transcripts were PCR-amplified for 35 cycles using high-specificity primer pairs designed to minimize cross-hybridization between CaMKII genes (Supplementary table XX) using either Phusion polymerase (NEB #M0530) or KAPA HiFi polymerase (Roche). This yielded a mixed population of variable-length amplicons reflecting the splice variants of the targeted gene present in the starting sample.

Construction of Illumina Sequencing Libraries

Illumina sequencing libraries were prepared from the initial variable-length amplicon pools using an adapted PCR-based construction protocol (38). Briefly: first, gene-specific primers with overhangs containing Illumina-specified sequences (Fig. 2B, supplementary file S2) were used to sub-amplify transcript variable regions. Second, generic primers annealing to the overhangs introduced in the first reaction were used to incorporate annealing sites for Illumina sequencing primers, NEBNext library indices (NEB #E7335 single-index set, #E7600 dual-index set), and P5/P7 flow cell annealing sequences. The resulting amplicons were agarose gel-purified with size selection based on the theoretical minimal (no linker exons spliced in) and maximal (all linker exons spliced in) lengths of the variable region inserts.

Analysis of Illumina Sequencing

Illumina reads were grouped by sequence similarity, producing clusters with >90% sequence identity and two or fewer base pair insertions/deletions. The consensus sequence of each cluster was aligned to exon sequences from the corresponding CaMKII gene obtained from the reference human genome (GRCh38.p12, Ensembl release 95) in order to map exon order in the transcript represented by the cluster. Over 90% of clustered reads from each Illumina library were unambiguously mapped with reference exons of the corresponding gene, with all splice junctions matching those observed in previously annotated splice variants. We refer to these as mapped reads. Python2 code implementing read clustering is available at github.com/romansloutsky/illumina_read_clustering.

Two technical replicates of libraries were prepared from the donor 1 tissue sample, starting with the initial reverse transcription step, and sequenced. One replicate each from donors 2 and 3 was sequenced. For each gene, different collections of splice variants were detected in each of the four cDNA samples, so calculating the correlation between replicates across all detected variants is not possible. Instead, for each gene we calculated pairwise Pearson correlation in variant detection levels (fraction of mapped reads which mapped to that variant) and Spearman rank-based correlation between replicates over only those variants that were detected in all four replicates (Table S19). While Pearson correlation between replicates and donors is over 90% for most pairwise comparisons, it is dominated by the magnitude of differences between the strongest- and weakest-detected variants. When the highest detected variants differ between samples, Pearson correlation plunges. Technical replicates are no better correlated than biological replicates, indicating substantial variability between library preps and sequencing reactions. This is not unexpected, given 93 total cycles of PCR amplification, as well as the known run-to-run variability in flow cell clustering efficiency when sequencing mixtures of inserts of different lengths. Spearman correlation generally tracks with Pearson correlation, but is less skewed by the magnitude of highest-detected variants. On the whole, Spearman correlation indicates a limited ability to accurately order variants according to detection level. We believe the highest resolution of detection level quantification possible from these sequencing experiments is the categorization of variants into several detection level ranges. We used ‘high’ (roughly 20% or more of mapped reads), ‘medium’ (roughly between 20% and 5%), ‘low’ (roughly between 5% and 1%), and ‘trace’ (roughly below 1%) categories. We then classified transcripts as consistent (in same detection level category) or inconsistent (different detection level categories) between donors. Allowing for observed variation between technical replicates,

and considering ‘trace’ detection (typically fewer than 50, but always more than 5 reads) in some replicates consistent with no detection in others, the overwhelming majority of variants were detected at a consistent level between all three individuals (Table S9). We believe the remaining, inconsistent variants reflect physiological differences between individuals.

Plasmid construction

Full-length CaMKII variants were cloned into a pET vector containing N-terminal 6xHis followed by a SUMO tag. CaMKII chimeras were constructed as follows. The kinase/regulatory segment and hub domains of CaMKII α and CaMKII β were amplified from full-length constructs. The kinase domain includes the regulatory segment of its corresponding kinase. Each domain was amplified with a 20 bps overhang that was the corresponding CaMKII gene. The chimeras were assembled using Gibson assembly.

Protein expression and purification

All CaMKII variants used for this experiment were recombinantly expressed and purified according to (39). Plasmids encoding CaMKII variants were co-transformed with lambda phosphatase into Rosetta 2(DE3)pLysS competent cells (Millipore). Expression was induced overnight with 1mM Isopropyl β -D-1-thiogalactopyranoside (IPTG, GoldBio) and cultures were grown overnight at 18 °C. Cell pellets were resuspended in Buffer A (25 mM Tris-HCl pH 8.5, 150 mM KCl, 50 mM Imidazole, 10% glycerol) (Sigma) with 25 mM Magnesium chloride, containing a cocktail of protease inhibitors and DNase (AEBSF 0.2 mM, Leupeptin 0.005 mM, 1 μ g/mL Pepstatin, 1 μ g/mL Aprotinin, 0.1 mg/mL Trypsin Inhibitor, 0.5 mM Benzamidine, 1 μ g/mL DNase) (Sigma) and lysed. All subsequent purification steps were performed using an

ÄKTA pure chromatography system at 4°C. Clarified lysate was loaded onto a 5 mL HisTrap FF NiNTA Sepharose column (GE), and eluted with a combination of 50% Buffer A and 50% Buffer B (25mM Tris-HCl pH 8.5, 150mM KCl, 1M imidazole, 10% glycerol) for a final concentration of 0.5 M imidazole. The protein was desalted of residual imidazole using a HiPrep 26/10 Desalting column, and His SUMO tags were cleaved with Ulp1 protease overnight at 4°C in Buffer C (25mM Tris-HCl pH 8.5, 150mM KCl, 2mM TCEP (GoldBio), 50mM Imidazole, 10% glycerol). Cleaved tags were separated by a subtractive NiNTA step. Next, an anion exchange step was done using a 5 mL HiTrap Q-FF and protein was eluted with a KCl gradient. Eluted proteins were concentrated and further purified in gel filtration buffer (25mM Tris-HCl pH 8.0, 150mM KCl, 1mM TCEP, 10% glycerol) using a Superose 6 Increase 10/300 size exclusion column. Pure fractions were then concentrated, aliquoted, flash frozen in liquid nitrogen and stored at -80°C until further use. All columns were purchased from GE.

Calmodulin (*Gallus gallus*) was recombinantly expressed from a pET-15b vector (generous gift from Angus Nairn) in BL21(DE3) cells (Millipore) and purified as previously described (40). To quantify the calmodulin concentration for making stocks to use in the kinase assays, we used circular dichroism on a Jasco J-1500 Spectrophotometer to make a measurement in triplicate for our purified sample scanning a wavelength spectrum between 250-215 nm to measure the characteristic wavelength of 222 nm according to (41).

Equation used to calculate calmodulin concentration:

$$[\text{calmodulin}](\text{nM}) = \frac{1000 \times (CD_{\text{sample}}^{222\text{nm}} - CD_{\text{blank}}^{222\text{nm}})}{\Theta \times l \times \text{number of amino acids}}$$

where circular dichroism at 222 nm ($CD^{222\text{nm}}$) is expressed in mdeg, Θ is the molar ellipticity, and l is the path length in cm.

Coupled kinase assays

Kinase activity was monitored with previously described conditions (29,42) using a Synergy H1 microplate reader (Biotek). The addition of calmodulin (concentrations ranging from 0nM-2μM) to the reaction was used to initiate CaMKII activity, after which absorbance was measured at 15 second intervals for 10 minutes. The change in absorbance over the course of the resulting time series of measurements was fit with a straight line ($y = mx + c$) to obtain a slope (m) proportional to the kinetic rate of the reaction. For each time series, slopes were fit to a sliding window of 5 points (1 minute 15 seconds) and the maximum observed slope was used to represent the kinetic rate of that reaction. Kinetic rates across a series of calmodulin concentrations were fit with the following equation:

$$Y = Y_{min} + \frac{(Y_{max} - Y_{min}) \cdot X^{n_H}}{X^{n_H} + EC_{50}^{n_H}}$$

to obtain EC_{50} (defined as the calmodulin concentration needed to reach half the maximal reaction velocity) and cooperativity values (Hill coefficients, n_H). 95% confidence intervals for fit parameters (EC_{50} and n_H) were determined using the following bootstrap procedure. 10,000 replicate calmodulin concentration series were generated by randomly selecting one observed kinetic rate at each measured calmodulin concentration from the set of replicates for that variant. Each generated concentration series was fit with the equation above. Parameter values at the 2.5th and 97.5th quantiles of the 10,000 fits were taken as the boundaries of the 95% confidence interval.

Assay Component	Final concentration in Master Mix
Calcium (CaCl ₂), Sigma	0.2 mM
Pyruvate Kinase, Sigma	55.7 U/ml
Lactate Dehydrogenase, Millipore Sigma	78 U/ml
Adenosine triphosphate, Sigma	0.5 mM
Phosphoenolpyruvate, Alfa Aesar	1 mM
Nicotinamide adenine dinucleotide, Sigma	0.2 mg/ml
Syntide, LifeTein	0.3 mM
KCl, Sigma	150 mM
Tris/MgCl ₂ Buffer, Fisher Scientific	50 mM/10 mM

The final pH of each reaction was ~7.5-8, and the final enzyme concentration was 133 nM.

Small Angle X-ray Scattering

Small Angle X-ray Scattering (SAXS) data were collected at the mail-in high-throughput SIBYLS beamline 12.3.1 at the Advanced Light Source (ALS) using a Pilatus3 2M pixel array detector (Dectris). 20 μ l samples were loaded in a 1.5 mm thick chamber by an automated Tecan Freedom Evo liquid handling robot (43). Incident X-rays were tuned to a wavelength of 11keV/1.27Å, samples were exposed for 10 seconds and data collected every 0.1 or 0.33 sec. SAXS data were collected for CaMKII α -0 at concentrations: 1, 3, 7.2 mg/mL, and CaMKII β -0 at 3, 7, 11.5 mg/mL. Frames were chosen using SAXS Frameslice (<https://bl1231.als.lbl.gov/ran>). Data were then scaled and merged using the low q region from the lowest concentration datasets. R_g and D_{max} were determined using both Scatter 3.0 and primus (ATSAS 3.0).

Cryo-electron microscopy data collection and analysis

C-flat Holey Carbon grids with gold support (CF-1.2/1.3-3Au-50, EMS) were made hydrophilic by glow-discharging at 30 mA for 30 s using PELCO easiGlow (Ted Pella). 3 μ l of purified CaMKII at 0.5-5 mg/ml was applied to these grids at ~96% relative humidity, blotted for 5 s and plunge-frozen into liquid ethane using Cryoplunge 3 (Gatan).

Frozen hydrated samples were imaged on a FEI Talos Arctica at 200 kV with K2 Summit direct detection camera in super-resolution mode with a total exposure dose of around 52 electrons. Thirty-five frames per movie were collected at a magnification corresponding to 0.455 Å per pixel using SerialEM (44). Micrographs (6510) were collected at defocus values ranging from -0.5 to -2.5 μ m. Movie frames were motion-corrected and dose-weighted by MotionCor2 (45), sampled to 0.91 Å per pixel and contrast transfer function (CTF) parameters were estimated by CTFIND4 (46). Particle picking was carried out using crYOLO giving 1,500,734 initial particles. Initial *ab-initio* models were generated in Relion (47). Following successive rounds of 2D and 3D classification 290,980 particles were selected. An additional rounds of 3D classification led to the reconstructions of 4.8 Å from 160,211 particles (reconstruction Class A), of 6.6 Å from 40,329 particles (reconstruction Class B, fig. S4).

Maps used for figures were filtered according to local resolution with b-factor sharpening within Relion. Models were fit into the map using Chimera (48) and Coot (49) and rigid body refined with PHENIX (50).

Supplementary Materials

fig. S1. PCR amplicons from multiple CaMKII β variants do not separate on agarose gel.

fig. S2. Data and EC₅₀ fits for all tested CaMKII variants.

fig. S3. SAXS data and analysis.

fig. S4. Cryo-EM data

Table S1. Detected CaMKII α splice variants.

Table S2. Read counts of CaMKII α splice variants from Donor 1

Table S3. Read counts of CaMKII α splice variants from Donor 2

Table S4. Read counts of CaMKII α splice variants from Donor 3

Table S5. Detected CaMKII β splice variants

Table S6. Read counts of CaMKII β splice variants from Donor 1

Table S7. Read counts of CaMKII β splice variants from Donor 2

Table S8. Read counts of CaMKII β splice variants from Donor 3

Table S9. Detected CaMKII γ splice variants

Table S10. Read counts of CaMKII γ splice variants from Donor 1

Table S11. Read counts of CaMKII γ splice variants from Donor 2

Table S12. Read counts of CaMKII γ splice variants from Donor 3

Table S13. Detected CaMKII δ splice variants

Table S14. Read counts of CaMKII δ splice variants from Donor 1

Table S15. Read counts of CaMKII δ splice variants from Donor 2

Table S16. Read counts of CaMKII δ splice variants from Donor 3

Table S17. Pearson and Spearman correlation matrices for CaMKII β variants

Table S18. Pearson and Spearman correlation matrices for CaMKII γ variants

Table S19. Pearson and Spearman correlation matrices for CaMKII δ variants

Data file S1. Exon sequences for all CaMKII genes

Data file S2. Primers for initial amplification of variably spliced transcript regions

References

1. Lin, Y. C., and Redmond, L. (2009) Neuronal CaMKII acts as a structural kinase. *Communicative & integrative biology* **2**, 40-41
2. Escoffier, J., Lee, H. C., Yassine, S., Zouari, R., Martinez, G., Karaouzene, T., Coutton, C., Kherraf, Z. E., Halouani, L., Triki, C., Nef, S., Thierry-Mieg, N., Savinov, S. N., Fissore, R., Ray, P. F., and Arnoult, C. (2016) Homozygous mutation of PLCZ1 leads to defective human oocyte activation and infertility that is not rescued by the WW-binding protein PAWP. *Hum Mol Genet* **25**, 878-891
3. Yoon, S. Y., Jellerette, T., Salicioni, A. M., Lee, H. C., Yoo, M. S., Coward, K., Parrington, J., Grow, D., Cibelli, J. B., Visconti, P. E., Mager, J., and Fissore, R. A. (2008) Human sperm devoid of PLC, zeta 1 fail to induce Ca(2+) release and are unable to initiate the first step of embryo development. *The Journal of clinical investigation* **118**, 3671-3681
4. Backs, J., Backs, T., Neef, S., Kreusser, M. M., Lehmann, L. H., Patrick, D. M., Grueter, C. E., Qi, X., Richardson, J. A., Hill, J. A., Katus, H. A., Bassel-Duby, R., Maier, L. S., and Olson, E. N. (2009) The delta isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload. *Proc Natl Acad Sci U S A* **106**, 2342-2347
5. Cook, S. G., Bourke, A. M., O'Leary, H., Zaegel, V., Lasda, E., Mize-Berge, J., Quillinan, N., Tucker, C. L., Coultrap, S. J., Herson, P. S., and Bayer, K. U. (2018) Analysis of the CaMKII alpha and beta splice-variant distribution among brain regions reveals isoform-specific differences in holoenzyme formation. *Sci Rep-Uk* **8**
6. Maier, L. S., and Bers, D. M. (2002) Calcium, calmodulin, and calcium-calmodulin kinase II: heartbeat to heartbeat and beyond. *Journal of molecular and cellular cardiology* **34**, 919-939
7. Tombes, R. M., Faison, M. O., and Turbeville, J. M. (2003) Organization and evolution of multifunctional Ca(2+)/CaM-dependent protein kinase genes. *Gene* **322**, 17-31
8. Lisman, J., Yasuda, R., and Raghavachari, S. (2012) Mechanisms of CaMKII action in long-term potentiation. *Nat Rev Neurosci* **13**, 169-182
9. Silva, A. J., Paylor, R., Wehner, J. M., and Tonegawa, S. (1992) Impaired spatial learning in alpha-calmodulin-calmodulin kinase II mutant mice. *Science* **257**, 206-211
10. Bachstetter, A. D., Webster, S. J., Tu, T., Goulding, D. S., Haiech, J., Watterson, D. M., and Van Eldik, L. J. (2014) Generation and behavior characterization of CaMKIIbeta knockout mice. *PLoS one* **9**, e105191

11. Giese, K. P., Fedorov, N. B., Filipkowski, R. K., and Silva, A. J. (1998) Autophosphorylation at Thr286 of the alpha calcium-calmodulin kinase II in LTP and learning. *Science* **279**, 870-873
12. Hanson, P. I., and Schulman, H. (1992) Inhibitory autophosphorylation of multifunctional Ca²⁺/calmodulin-dependent protein kinase analyzed by site-directed mutagenesis. *J Biol Chem* **267**, 17216-17224
13. Rellos, P., Pike, A. C., Niesen, F. H., Salah, E., Lee, W. H., von Delft, F., and Knapp, S. (2010) Structure of the CaMKII δ /calmodulin complex reveals the molecular mechanism of CaMKII kinase activation. *PLoS Biol* **8**, e1000426
14. Patton, B. L., Miller, S. G., and Kennedy, M. B. (1990) Activation of type II calcium/calmodulin-dependent protein kinase by Ca²⁺/calmodulin is inhibited by autophosphorylation of threonine within the calmodulin-binding domain. *J Biol Chem* **265**, 11204-11212
15. Meyer, T., Hanson, P. I., Stryer, L., and Schulman, H. (1992) Calmodulin trapping by calcium-calmodulin-dependent protein kinase. *Science* **256**, 1199-1202
16. Bhattacharyya, M., Stratton, M. M., Going, C. C., McSpadden, E. D., Huang, Y., Susa, A. C., Elleman, A., Cao, Y. M., Pappireddi, N., Burkhardt, P., Gee, C. L., Barros, T., Schulman, H., Williams, E. R., and Kuriyan, J. (2016) Molecular mechanism of activation-triggered subunit exchange in Ca/calmodulin-dependent protein kinase II. *eLife* **5**
17. Rosenberg, O. S., Deindl, S., Comolli, L. R., Hoelz, A., Downing, K. H., Nairn, A. C., and Kuriyan, J. (2006) Oligomerization states of the association domain and the holoenzyme of Ca²⁺/CaM kinase II. *FEBS J* **273**, 682-694
18. Myers, J. B., Zaegel, V., Coultrap, S. J., Miller, A. P., Bayer, K. U., and Reichow, S. L. (2017) The CaMKII holoenzyme structure in activation-competent conformations. *Nat Commun* **8**, 15742
19. Chao, L. H., Stratton, M. M., Lee, I. H., Rosenberg, O. S., Levitz, J., Mandell, D. J., Kortemme, T., Groves, J. T., Schulman, H., and Kuriyan, J. (2011) A mechanism for tunable autoinhibition in the structure of a human Ca²⁺/calmodulin-dependent kinase II holoenzyme. *Cell* **146**, 732-745
20. Ma, H., Groth, R. D., Cohen, S. M., Emery, J. F., Li, B., Hoedt, E., Zhang, G., Neubert, T. A., and Tsien, R. W. (2014) gammaCaMKII shuttles Ca(2+)(+)/CaM to the nucleus to trigger CREB phosphorylation and gene expression. *Cell* **159**, 281-294
21. Brocke, L., Srinivasan, M., and Schulman, H. (1995) Developmental and Regional Expression of Multifunctional Ca²⁺/Calmodulin-Dependent Protein-Kinase Isoforms in Rat-Brain. *Journal of Neuroscience* **15**, 6797-6808
22. Heist, E. K., Srinivasan, M., and Schulman, H. (1998) Phosphorylation at the nuclear localization signal of Ca²⁺/calmodulin-dependent protein kinase II blocks its nuclear targeting. *Journal of Biological Chemistry* **273**, 19763-19771
23. Kalderon, D., Roberts, B. L., Richardson, W. D., and Smith, A. E. (1984) A short amino acid sequence able to specify nuclear location. *Cell* **39**, 499-509
24. O'Leary, H., Lasda, E., and Bayer, K. U. (2006) CaMKII β association with the actin cytoskeleton is regulated by alternative splicing. *Mol Biol Cell* **17**, 4656-4665
25. Khan, S., Downing, K. H., and Molloy, J. E. (2019) Architectural Dynamics of CaMKII-Actin Networks. *Biophysical Journal* **116**, 104-119
26. Okamoto, K., Narayanan, R., Lee, S. H., Murata, K., and Hayashi, Y. (2007) The role of CaMKII as an F-actin-bundling protein crucial for maintenance of dendritic spine structure. *Proc Natl Acad Sci U S A* **104**, 6418-6423
27. Bayer, K. U., Lohler, J., and Harbers, K. (1996) An alternative, nonkinase product of the brain-specifically expressed Ca²⁺/calmodulin-dependent kinase II alpha isoform gene in skeletal muscle. *Mol Cell Biol* **16**, 29-36
28. Bayer, K. U., Harbers, K., and Schulman, H. (1998) alpha KAP is an anchoring protein for a novel CaM kinase II isoform in skeletal muscle. *Embo Journal* **17**, 5598-5605
29. Chao, L. H., Pellicena, P., Deindl, S., Barclay, L. A., Schulman, H., and Kuriyan, J. (2010) Intersubunit capture of regulatory segments is a component of cooperative CaMKII activation. *Nat Struct Mol Biol* **17**, 264-272
30. De Koninck, P., and Schulman, H. (1998) Sensitivity of CaM kinase II to the frequency of Ca²⁺ oscillations. *Science* **279**, 227-230
31. Bhattacharyya, M., Karandur, D., and Kuriyan, J. (2019) Structural Insights into the Regulation of Ca(2+)/Calmodulin-Dependent Protein Kinase II (CaMKII). *Cold Spring Harb Perspect Biol*

32. Kolodziej, S. J., Hudmon, A., Waxham, M. N., and Stoops, J. K. (2000) Three-dimensional reconstructions of calcium/calmodulin-dependent (CaM) kinase II α and truncated CaM kinase II α reveal a unique organization for its structural core and functional domains. *J Biol Chem* **275**, 14354-14359
33. Morris, E. P., and Torok, K. (2001) Oligomeric structure of alpha-calmodulin-dependent protein kinase II. *J Mol Biol* **308**, 1-8
34. Rosenberg, O. S., Deindl, S., Sung, R. J., Nairn, A. C., and Kuriyan, J. (2005) Structure of the autoinhibited kinase domain of CaMKII and SAXS analysis of the holoenzyme. *Cell* **123**, 849-860
35. Myers, J. B., Zaegel, V., Coultrap, S. J., Miller, A. P., Bayer, K. U., and Reichow, S. L. (2018) The CaMKII holoenzyme structure in activation-competent conformations (vol 8, 15742, 2017). *Nat Commun* **9**
36. Bhattacharyya, M., Stratton, M. M., Goings, C. C., McSpadden, E. D., Huang, Y., Susa, A. C., Elleman, A., Cao, Y. M., Pappireddi, N., Burkhardt, P., Gee, C. L., Barros, T., Schulman, H., Williams, E. R., and Kuriyan, J. (2016) Molecular mechanism of activation-triggered subunit exchange in Ca²⁺/calmodulin-dependent protein kinase II. *Elife* **5**
37. Bayer, K. U., De Koninck, P., and Schulman, H. (2002) Alternative splicing modulates the frequency-dependent response of CaMKII to Ca(2+) oscillations. *EMBO J* **21**, 3590-3597
38. Kanizay, L. B., Jacobs, T. B., Gillespie, K., Newsome, J. A., Spaid, B. N., and Parrott, W. A. (2015) HtStuf: High-Throughput Sequencing to Locate Unknown DNA Junction Fragments. *Plant Genome-Us* **8**
39. Stratton, M., Lee, I. H., Bhattacharyya, M., Christensen, S. M., Chao, L. H., Schulman, H., Groves, J. T., and Kuriyan, J. (2013) Activation-triggered subunit exchange between CaMKII holoenzymes facilitates the spread of kinase activity. *eLife* **3**, e01610
40. Putkey, J. A., and Waxham, M. N. (1996) A peptide model for calmodulin trapping by calcium/calmodulin-dependent protein kinase II. *J Biol Chem* **271**, 29619-29623
41. Harmat, V., Bocskai, Z., Naray-Szabo, G., Bata, I., Csutor, A. S., Hermecz, I., Aranyi, P., Szabo, B., Liliom, K., Vertessy, B. G., and Ovadi, J. (2000) A new potent calmodulin antagonist with arylalkylamine structure: crystallographic, spectroscopic and functional studies. *J Mol Biol* **297**, 747-755
42. Barker, S. C., Kassel, D. B., Weigl, D., Huang, X., Luther, M. A., and Knight, W. B. (1995) Characterization of pp60c-src tyrosine kinase activities using a continuous assay: autoactivation of the enzyme is an intermolecular autophosphorylation process. *Biochemistry* **34**, 14843-14851
43. Hura, G. L., Menon, A. L., Hammel, M., Rambo, R. P., Poole, F. L., 2nd, Tsutakawa, S. E., Jenney, F. E., Jr., Classen, S., Frankel, K. A., Hopkins, R. C., Yang, S. J., Scott, J. W., Dillard, B. D., Adams, M. W., and Tainer, J. A. (2009) Robust, high-throughput solution structural analyses by small angle X-ray scattering (SAXS). *Nature methods* **6**, 606-612
44. Mastrorade, D. N. (2005) Automated electron microscope tomography using robust prediction of specimen movements. *Journal of structural biology* **152**, 36-51
45. Zheng, S. Q., Palovcak, E., Armache, J. P., Verba, K. A., Cheng, Y. F., and Agard, D. A. (2017) MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. *Nature methods* **14**, 331-332
46. Rohou, A., and Grigorieff, N. (2015) CTFFIND4: Fast and accurate defocus estimation from electron micrographs. *Journal of structural biology* **192**, 216-221
47. Zivanov, J., Nakane, T., Forsberg, B. O., Kimanius, D., Hagen, W. J. H., Lindahl, E., and Scheres, S. H. W. (2018) New tools for automated high-resolution cryo-EM structure determination in RELION-3. *Elife* **7**
48. Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., and Ferrin, T. E. (2004) UCSF chimera - A visualization system for exploratory research and analysis. *J Comput Chem* **25**, 1605-1612
49. Emsley, P., Lohkamp, B., Scott, W. G., and Cowtan, K. (2010) Features and development of Coot. *Acta Crystallogr D* **66**, 486-501
50. Adams, P. D., Afonine, P. V., Bunkoczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L. W., Kapral, G. J., Grosse-Kunstleve, R. W., McCoy, A. J., Moriarty, N. W., Oeffner, R., Read, R. J., Richardson, D. C., Richardson, J. S., Terwilliger, T. C., and Zwart, P. H. (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallographica Section D-Structural Biology* **66**, 213-221

Acknowledgments: We thank Florian Heyd and Andreas Franz for helpful discussions on data and the manuscript. We also thank Peter Chien, Eric Strieter, Scott Garman for helpful discussions. We thank Greg Hura and Kathryn Burnett for SAXS data collection and help with analysis. SAXS data was collected at the Advanced Light Source (ALS), SIBYLS beamline on behalf of US DOE-BER, through the Integrated Diffraction Analysis Technologies (IDAT) program. Additional support comes from the NIGMS project ALS-ENABLE (P30 GM124169) and a High-End Instrumentation Grant S10OD018483. Cryo-EM data were collected at the Harvard Cryo-EM Center for Structural Biology. We are grateful for support from Sarah Sterling, Richard Walsh, Shaun Rawson and Zongli Li for cryo-EM data collection.

Funding: Funding was provided by the University of Massachusetts, Amherst and a grant to MMS from the National Institute of General Medical Sciences (R01GM123157), ND and AT were supported by National Research Service Award (T32GM008515) from the National Institutes of Health, as part of the UMass Chemistry-Biology Interface Training Program.

Author contributions: RS and ND designed experiments, collected and analyzed data, wrote and edited manuscript. MD, RB, AT, BP, JW, SB, LC collected data. MS and LC designed experiments, analyzed data, wrote and edited manuscript.

Competing interests: The authors declare that they have no competing interests.

Data and Materials Availability: Cryo-EM maps and models to be deposited into EMDB and the PDB.

Figures




Figure 1. CaMKII sequence divergence and structural organization. (A) Each subunit of CaMKII consists of a kinase domain, regulatory segment, variable linker region, and hub domain. The regulatory segment houses the calmodulin binding region as well as a regulatory autophosphorylation site, Thr²⁸⁶. (B) The regulatory segment acts as an autoinhibitory domain by blocking the substrate-binding pocket. In the presence of Ca²⁺, Ca²⁺-CaM binds the regulatory segment, exposing the substrate-binding pocket and turning the enzyme on. (C) The hub domain oligomerizes CaMKII into two stacked hexameric rings. Shown is a cartoon of an active structure with Ca²⁺-CaM bound to the regulatory segment. (D) Neighbor Joining reconstructions of kinase and hub domain divergence for the four human CaMKII genes, rooted with *D. melanogaster* CaMKII outgroups.




Figure 2. Illumina sequencing reveals a heterogeneous population of CaMKII variants in the human hippocampus. (A) Human CaMKII genes are encoded by 24 exons with clear one-to-one correspondence across genes. Exons 1-10 encode the catalytic kinase domain, 11 and 12

encode the regulatory segment, 13-21 encode the variable-length linker, and 22-24 encode the association (hub) domain. Missing linker exons indicate that the exon is not encoded in the corresponding gene. Constitutively incorporated kinase, regulatory segment, and hub exons (grey) are spliced into every transcript. CaMKII δ encodes two versions of kinase exon 6, with one or the other, but not both, incorporated into transcripts. Several exons contain alternative splice sites, permitting omission of a fraction of the exon (indicated by hatching). CaMKII β encodes three nearly identical proline-rich linker exons: 19-21, homologous to CaMKII γ exon 19. **(B)** Illumina library construction is illustrated with CaMKII β . Initial PCR amplification of a region encompassing all alternative splice sites (including the linker and hub exon 23) is carried out with primers designed for specificity for target CaMKII gene, to the exclusion of the other three genes (orange and red arrows). Initial amplicons serve as templates for amplification of library inserts in a second PCR reaction with a different primer pair (green and blue arrows). Resulting inserts are fully spanned by paired-end 251bp reads for nearly all splice variants. For CaMKII β , this is true as long as exons 19, 20, and 21 are not incorporated. These exons are shown as semi-transparent because they were not incorporated in any detected hippocampal splice variant. **(C)** Summary of CaMKII α and β transcript variants for 2 replicates of Donor 1 (r1, r2), Donor 2, and Donor 3 as detected by Illumina sequencing. All detected variants, including all previously annotated variants, are shown for CaMKII α . For CaMKII β , the top eight read-mapping variants are shown above the black line and the remaining previously annotated variants are shown below the line. Variants are marked as ‘unreported’ if they have not been previously annotated or ‘undetected’ if we did not detect the transcript in our experiment. Underlined percentages indicate inconsistency between libraries. Variants highlighted in blue are those that were used in activity measurements (see Fig. 3).




Figure 3. The hub domain plays a crucial role in Ca²⁺/CaM sensitivity. CaMKII activity against a peptide substrate (syntide) was measured as a function of Ca²⁺-CaM concentration. To simplify comparisons, fit curves were normalized by the corresponding V_{max} fit parameter and

data points are not shown (see fig. S3). The EC_{50} value for each fit is indicated by a single box, and dashed gray lines in B-D indicate reference EC_{50} values for CaMKII α -30 and CaMKII α -0 (B) or CaMKII β -0 and CaMKII α -0 (C, D), as labeled on the X-axis. Activity measurements and EC_{50} and n_H (Hill coefficient) fit parameters are shown for all three CaMKII α splice variants (A), eight selected CaMKII β variants (B), chimeras of CaMKII α/β with no linker (C), and CaMKII γ and δ with no linker (D). EC_{50} and Hill coefficient (n_H) fit parameters with 95% confidence intervals (see Materials and Methods) are listed for each tested variant, N=3 titrations for each protein sample. Cartoon representations of CaMKII holoenzymes in their autoinhibited states are shown in panel A. For panels C and D, each domain is labeled according to the CaMKII gene.




Figure 4. Allosteric contributions from the hub domain regulate CaMKII activation. (A)

The 32 positions that differ between CaMKII α and β hubs are represented by spheres at the alpha Carbon position on the structure of CaMKII α hub (pdb: 3SOA). Hub is shown in cyan, regulatory segment in orange, and kinase domain in green. **(B)** Sequence alignment of CaMKII α , β , γ , and δ hub domains, colored by degree of conservation (dark to light = most to least conserved). For convenience, all hub sequences start at residue 1. Residues in CaMKII α hub that

differ in CaMKII β are highlighted by red boxes. The loop mediating kinase docking in the Class B cryo-EM reconstruction is shown in the black box.





Figure 5. 2D classes of single particle cryo-EM analysis of CaMKII α -30. (A) 6- and 7-fold symmetric top views for CaMKII holoenzymes were observed cryo-EM 2D classes. (B) Example of a clearly visible side views in the 2D classes. (C) Density for a single kinase domain (blue

arrow) docked onto a dodecameric central hub seen in a top view. (D) Density for multiple kinase domains (blue arrows) above the hub midplane is visible in side views. (E) Density for kinase domains remain when the mask diameter is increased to 300 Å. No additional ordered density is visible at extended positions.

A



B




Figure 6. Two kinase domain arrangements observed by cryo-EM. (A) In reconstruction

Class A, a single kinase domain is resolved, between two hub domain subunits. A kinase domain

from the CaMKII α -0 holoenzyme crystal structure (pdb: 3SOA) was fit into the additional density. (B) In a second reconstruction, Class B, a kinase domain is visible interacting with a hub subunit with the kinase C-lobe making contact with a loop at the top of the hub domain. CaMKII α kinase domain (pdb: 3SOA) docked into the additional density, CaMKII hub domain (pdb: 5IG3) docked into the hub density.

Supplementary Materials:




Fig. S1. PCR amplicons from multiple CaMKII β variants do not separate on agarose gel. A PCR reaction with CaMKII β -specific primers was loaded onto a 2.5% agarose gel and run at 10V for roughly 24hrs (pictured below) for optimal band separation. The single visible band was excised, purified, and Sanger-sequenced. A fragment of the resulting sequencing trace is shown, with height of grey background representing Phred quality scores. The first 15bp of the fragment (left of grey line) map to the last 15bp of CaMKII β constitutive exon 12, incorporated into every

CaMKII β transcript. The last 15bp of the fragment (right of grey line) show a dramatic increase of secondary peak heights, with a corresponding drop-off in Phred scores. The sequence defined by primary peaks (TGGGCAGACAGACCA) maps to CaMKII β linker exon 13. Variants β 13,14b,16,17,18 (44.8%), β 13,14b,16,18 (5.9%), β 13,14b,17,18 (4.0%), β 13,14b,16,17,18-short-hub (3.7%) accounted for roughly 58.4% of mapped reads from the CaMKII β Illumina library. Variants in which exon 14a (CAGCCAAGAGTTTAC) followed exon 12, such as β 14a,16,18 (13.8%) and β 14a,16,17,18 (9.1%), accounted for roughly 30% of mapped reads. Variants in which exon 14b (CCAAGAGTTTACTCA) followed exon 12, such as β 14a,16,17,18 (7.1%), β 14a,16,18 (6.3%), and β 14a,17,18 (1.2%) accounted for roughly 14% of mapped reads. Secondary peaks corresponding to exons 14a and 14b are clearly visible in the last 15bp of the Sanger sequencing fragment.




Fig. S2. Data and EC_{50} fits for all tested CaMKII variants. Data point color reflects

replicates.




Fig. S3. SAXS data and analyses of CaMKII α -0 and CaMKII β -0. Scattering curves, Guinier plots and Kratky plots were made using Primus (ATSAS 3.0). Pair distribution functions were made using Scatter 3.0.




Fig. S4. Cryo-EM data

(A) Fourier shell correlation (FSC) curves obtained from Relion 3 postprocess job for Class A reconstruction. The resolution is estimated at FSC = 0.143. (B) Angular distribution of the final reconstruction obtained from Relion for Class A. (C) Fourier shell correlation (FSC) curves obtained from Relion 3 postprocess job for Class B reconstruction. The resolution is estimated at

FSC = 0.143. (D) (B) Angular distribution of the final reconstruction obtained from Relion for Class B.

Variant name	CCDS identifier	Percent of mapped reads				Expression level	Expression pattern
CaMKIIα							
		Donor1 r1	Donor1 r2	Donor2	Donor3		
14,18	CCDS43386	94.6	70.19	93.12	94.46	high	consistent
no-linker	<i>unreported</i>	3.89	25.36	6.39	0.48	medium / low	inconsistent
14,15,18	CCDS43387	1.52	4.45	0.49	5.06	low / trace	inconsistent

Table S1. Detected CaMKII α splice variants

CaMKII α				
Donor 1				
Replicate 1			Replicate 2	
Variant	Read count	% mapped	Read count	% mapped
14,18	183118	94.6	81521	70.2
no-linker	7527	3.89	29449	25.4
14,15,18	2941	1.52	5170	4.45
Total	193586		116140	

Table S2. Read counts of CaMKII α splice variants from Donor 1

CaMKII α		
Donor 2		
Variant	Read count	% mapped
14,18	81002	93.1
no-linker	5558	6.39
14,15,18	426	0.49
Total	86986	

Table S3. Read counts of CaMKII α splice variants from Donor 2

CaMKII α		
Donor 3		
Variant	Read count	% mapped
14,18	53383	94.5
no-linker	2862	5.06
14,15,18	271	0.48
Total	56516	

Table S4. Read counts of CaMKII α splice variants from Donor 3

Variant name	CCDS identifier	Percent of mapped reads				Expression level	Expression pattern
CaMKIIβ							
		Donor1 r1	Donor1 r2	Donor2	Donor3		
13,14b,16,17,18,full	CCDS5484	44.83	56.31	54.02	36.63	high	consistent
14a,16,18,full	CCDS5486	13.78	5.85	6.59	7.40	medium	consistent
14a,16,17,18,full	CCDS5485	9.11	6.99	6.06	9.34	medium	consistent
14b,16,17,18,full	CCDS43573	7.08	5.73	3.95	6.50	medium	consistent
14b,17,18,full	<i>unreported</i>	1.16	5.74	14.35	4.46	medium / low	inconsistent
13,14b,16,18,full	<i>unreported</i>	5.89	5.13	2.62	6.00	medium	consistent
13,14b,17,18,full	<i>unreported</i>	3.97	3.51	1.92	10.30	medium / low	inconsistent
14b,16,18,full	<i>unreported</i>	6.28	2.08	1.50	3.21	low	consistent
13,14b,18,full	<i>unreported</i>	0.63	4.29	4.25	1.28	low	consistent
14a,17,18,full	<i>unreported</i>	0.83	1.35	2.39	2.32	low	consistent
13,14b,16,17,18,short	<i>unreported</i>	3.72	1.12	0.03	2.56	low / trace	inconsistent
14a,18,full	CCDS5488	0.51	0.58	1.95	1.83	low	consistent
14b,18,full	<i>unreported</i>	0.24	0.26	0.34	0.53	trace	consistent
13,14a,16,17,18,full	<i>unreported</i>	0.28	0.23	0.02	0.10	trace	consistent
14b,16,17,18,short	<i>unreported</i>	0.43	0.13	N	0.43	trace	consistent
13,14b,16,18,short	<i>unreported</i>	0.27	0.10	N	0.45	trace	consistent
14a,16,17,18,short	<i>unreported</i>	0.21	0.08	N	0.66	trace	consistent
13,14b,17,18,short	CCDS5487	0.10	0.08	N	0.83	trace	consistent
14a,16,18,short	<i>unreported</i>	0.21	0.08	N	0.35	trace	consistent
14b,16,18,short	<i>unreported</i>	0.07	0.13	N	0.23	trace	consistent
no-linker,full	CCDS5489	0.13	N	N	3.67	low / trace	inconsistent
14a,17,18,short	<i>unreported</i>	0.11	N	N	0.15	trace	consistent
13,full	<i>unreported</i>	0.04	N	N	0.08	trace	consistent
14b,17,18,short	<i>unreported</i>	N	0.07	N	0.22	trace	consistent
13,14a,16,18,full	<i>unreported</i>	0.12	N	N	N	trace	consistent
16,17,18,full	<i>unreported</i>	N	0.16	N	N	trace	consistent
13,14b,18,short	<i>unreported</i>	N	0.04	N	N	trace	consistent
18,full	<i>unreported</i>	N	N	N	0.22	trace	consistent
no-linker,short	<i>unreported</i>	N	N	N	0.15	trace	consistent
14b,18,short	<i>unreported</i>	N	N	N	0.08	trace	consistent

Table S5. Detected CaMKII β splice variants

CaMKII β					
Donor 1					
Replicate 1			Replicate 2		
Variant	Read count	% mapped	Variant	Read count	% mapped
13,14b,16,17,18,full	65577	44.83	13,14b,16,17,18,full	23166	56.3
14a,16,18,full	20153	13.8	14a,16,17,18,full	2875	6.99
14a,16,17,18,full	13327	9.11	14a,16,18,full	2405	5.85
14b,16,17,18,full	10362	7.08	14b,17,18,full	2363	5.74
14b,16,18,full	9192	6.28	14b,16,17,18,full	2358	5.73
13,14b,16,18,full	8616	5.89	13,14b,16,18,full	2109	5.13
13,14b,17,18,full	5805	3.97	13,14b,18,full	1765	4.29
13,14b,16,17,18,short	5442	3.72	13,14b,17,18,full	1446	3.51
14b,17,18,full	1700	1.16	14b,16,18,full	855	2.08
14a,17,18,full	1218	0.83	14a,17,18,full	555	1.35
13,14b,18,full	928	0.63	13,14b,16,17,18,short	459	1.12
14a,18,full	750	0.51	14a,18,full	237	0.58
14b,16,17,18,short	634	0.43	14b,18,full	105	0.26
13,14a,16,17,18,full	412	0.28	13,14a,16,17,18,full	94	0.23
13,14b,16,18,short	400	0.27	16,17,18,full	64	0.16
14b,18,full	352	0.24	14b,16,18,short	52	0.13
14a,16,17,18,short	309	0.21	14b,16,17,18,short	52	0.13
14a,16,18,short	303	0.21	13,14b,16,18,short	41	0.10
no-linker,full	185	0.13	13,14b,17,18,short	33	0.08
13,14a,16,18,full	169	0.12	14a,16,18,short	33	0.08
14a,17,18,short	155	0.11	14a,16,17,18,short	32	0.08
13,14b,17,18,short	148	0.10	14b,17,18,short	27	0.07
14b,16,18,short	104	0.07	13,14b,18,short	17	0.04
13,full	52	N	Total	41143	
Total	146293				

Table S6. Read counts of CaMKII β splice variants from Donor 1

CaMKII β		
Donor 2		
Variant	Read count	% mapped
13,14b,16,17,18,full	28645	54.0
14b,17,18,full	7609	14.4
14a,16,18,full	3495	6.59
14a,16,17,18,full	3215	6.06
13,14b,18,full	2255	4.25
14b,16,17,18,full	2095	3.95
13,14b,16,18,full	1390	2.62
14a,17,18,full	1269	2.39
14a,18,full	1036	1.95
13,14b,17,18,full	1016	1.92
14b,16,18,full	795	1.50
14b,18,full	178	0.34
13,14b,16,17,18,short	15	0.03
13,14a,16,17,18,full	11	0.02
Total	53024	

Table S7. Read counts of CaMKII β splice variants from Donor 2

CaMKII β		
Donor 3		
Variant	Read count	% mapped
13,14b,16,17,18,full	18165	36.6
13,14b,17,18,full	5107	10.3
14a,16,17,18,full	4629	9.34
14a,16,18,full	3669	7.40
14b,16,17,18,full	3225	6.50
13,14b,16,18,full	2977	6.00
14b,17,18,full	2212	4.46
no-linker,full	1821	3.67
14b,16,18,full	1591	3.21
13,14b,16,17,18,short	1270	2.56
14a,17,18,full	1149	2.32
14a,18,full	907	1.83
13,14b,18,full	637	1.28
13,14b,17,18,short	413	0.83
14a,16,17,18,short	328	0.66
14b,18,full	263	0.53
13,14b,16,18,short	224	0.45
14b,16,17,18,short	215	0.43
14a,16,18,short	172	0.35
14b,16,18,short	116	0.23
18,full	110	0.22
14b,17,18,short	108	0.22
14a,17,18,short	75	0.15
no-linker,short	72	0.15
13,14a,16,17,18,full	49	0.10
13,full	42	0.08
14b,18,short	40	0.08
Total	49586	

Table S8. Read counts of CaMKII β splice variants from Donor 3

Variant name	CCDS identifier	Percent of mapped reads				Expression level	Expression pattern
CaMKIIγ							
		Donor1 r1	Donor1 r2	Donor2	Donor3		
14,16a,17,18b	CCDS7337	28.00	33.34	38.28	23.91	high	consistent
14,16a,17,18b,19a	CCDS7338	31.34	20.55	17.46	6.48	high / medium	inconsistent
14,15,17,18b	<i>unreported</i>	11.60	12.35	4.97	32.52	high / medium	inconsistent
14,17,18b	CCDS7336	6.01	13.04	21.14	13.25	high / medium	inconsistent
14,17,18b,19a	<i>unreported</i>	8.65	7.88	8.21	3.21	medium	consistent
14,15,17,18b,19a	<i>unreported</i>	7.10	6.13	1.85	6.11	medium / low	inconsistent
14,16b,17,18b	<i>unreported</i>	1.91	2.06	3.38	3.02	low	consistent
14,16b,17,18b,19a	<i>unreported</i>	2.69	1.51	1.61	0.98	low	consistent
14,15,16a,17,18b	<i>unreported</i>	1.29	1.36	0.32	1.77	low / trace	inconsistent
14,18b	<i>unreported</i>	0.05	0.83	1.92	1.67	low / trace	inconsistent
14,18b,19a	<i>unreported</i>	0.09	0.40	0.87	0.35	trace	consistent
14,15,18b	<i>unreported</i>	0.08	0.25	N	1.82	low / trace	inconsistent
14,15,18b,19a	<i>unreported</i>	N	0.18	N	0.22	trace	consistent
14,15	<i>unreported</i>	0.07	N	N	0.18	trace	consistent
14,15,16b,17,18b	<i>unreported</i>	0.06	N	N	0.13	trace	consistent
14,16a,18b	<i>unreported</i>	N	0.13	N	0.12	trace	consistent
14,15,16a,17,18,19a	<i>unreported</i>	0.97	N	N	N	trace	consistent
14,17,18a,19b	<i>unreported</i>	0.06	N	N	N	trace	consistent
14,15,16b,17,18b,19a	<i>unreported</i>	0.04	N	N	N	trace	consistent
no-linker	<i>unreported</i>	N	N	N	2.18	low / none	inconsistent
13,14,15,17,18b	<i>unreported</i>	N	N	N	0.29	trace	consistent
13,14,16a,17,18b	<i>unreported</i>	N	N	N	0.14	trace	consistent
14	<i>unreported</i>	N	N	N	0.13	trace	consistent
14,16a	<i>unreported</i>	N	N	N	0.11	trace	consistent

Table S9. Detected CaMKII γ splice variants

CaMKII γ					
Donor 1					
Replicate 1			Replicate 2		
Variant	Read count	% mapped	Variant	Read count	% mapped
14,16a,17,18b,19a	53510	31.3	14,16a,17,18b	11440	33.3
14,16a,17,18b	47800	28.0	14,16a,17,18b,19a	7051	20.5
14,15,17,18b	19801	11.6	14,17,18b	4475	13.0
14,17,18b,19a	14773	8.65	14,15,17,18b	4237	12.3
14,15,17,18b,19a	12127	7.10	14,17,18b,19a	2705	7.88
14,17,18b	10268	6.01	14,15,17,18b,19a	2102	6.13
14,16b,17,18b,19a	4586	2.69	14,16b,17,18b	708	2.06
14,16b,17,18b	3253	1.91	14,16b,17,18b,19a	517	1.51
14,15,16a,17,18b	2196	1.29	14,15,16a,17,18b	465	1.36
14,15,16a,17,18b,19a	1662	0.97	14,18b	285	0.83
14,18b,19a	160	0.09	14,18b,19a	136	0.40
14,15,18b	133	0.08	14,15,18b	87	0.25
14,15	111	0.07	14,15,18b,19a	61	0.18
14,15,16b,17,18b	100	0.06	14,16a,18b	45	0.13
14,17,18a,19b	96	0.06	Total	34314	
14,18b	81	0.05			
14,15,16b,17,18b,19a	72	0.04			
Total	170729				

Table S10. Read counts of CaMKII γ splice variants from Donor 1

CaMKII γ		
Donor 2		
Variant	Read count	% mapped
14,16a,17,18b	11647	38.3
14,17,18b	6433	21.1
14,16a,17,18b,19a	5314	17.5
14,17,18b,19a	2498	8.21
14,15,17,18b	1512	4.97
14,16b,17,18b	1029	3.38
14,18b	584	1.92
14,15,17,18b,19a	562	1.85
14,16b,17,18b,19a	489	1.61
14,18b,19a	265	0.87
14,15,16a,17,18b	96	0.32
Total	30429	

Table S11. Read counts of CaMKII γ splice variants from Donor 2

CaMKII γ		
Donor 3		
Variant	Read count	% mapped
14,15,17,18b	9131	32.5
14,16a,17,18b	6714	23.9
14,17,18b	3719	13.2
14,15,17,18b,19a	1716	6.11
14,16a,17,18b,19a	1820	6.48
14,17,18b,19a	900	3.21
14,16b,17,18b	849	3.02
no-linker	611	2.18
14,15,18b	512	1.82
14,15,16a,17,18b	497	1.77
14,18b	469	1.67
14,15,17,18b	395	1.41
14,16b,17,18b,19a	274	0.98
14,18b,19a	99	0.35
13,14,15,17,18b	82	0.29
14,15,18b,19a	63	0.22
14,15	51	0.18
13,14,16a,17,18b	38	0.14
14,15,16b,17,18b	37	0.13
14	36	0.13
14,16a,18b	33	0.12
14,16a	30	0.11
Total	30429	

Table S12. Read counts of CaMKII γ splice variants from Donor 3

Variant name	CCDS identifier	Percent of mapped reads				Expression level	Expression pattern
CaMKIIδ							
		Donor1 r1	Donor1 r2	Donor2	Donor3		
6v1,14b,18	CCDS82950	53.13	44.70	40.15	26.38	high	consistent
6v1,14a,18		29.04	33.59	21.63	33.65	high	consistent
6v1,14a,16,17,18	CCDS3703 CCDS3704 CCDS43263	7.62	11.56	20.78	15.59	medium	consistent
6v2,14b,18	<i>unreported</i>	4.70	0.89	5.74	2.86	low	consistent
6v2,14a,18	<i>unreported</i>	1.44	1.04	1.72	1.19	low	consistent
6v1,14b,16,17,18	<i>unreported</i>	0.10	0.61	0.07	1.09	trace	consistent
6v1,14a,17,18	<i>unreported</i>	1.32	3.45	N	9.53	medium / low / none	inconsistent
6v1,14b,17,18	CCDS47127	0.96	1.42	N	1.27	low / none	inconsistent
6v1,14a,15,17,18	<i>unreported</i>	0.11	N	6.18	2.35	low / trace	inconsistent
6v2,14a,17,18	<i>unreported</i>	0.66	0.07	N	1.26	low / none	inconsistent
6v1,14,15,16,17,18	<i>unreported</i>	0.03	0.20	N	0.17	trace	consistent
6v2,14b,16,17,18	<i>unreported</i>	N	0.03	1.92	0.07	low / trace	inconsistent
6v2,14a,16,17,18	<i>unreported</i>	N	N	2.15	3.26	low / none	inconsistent
6v1,14a	<i>unreported</i>	0.38	1.23	N	N	trace	consistent
6v1,14b	<i>unreported</i>	0.51	0.75	N	N	trace	consistent
6v2,14a,15,17,18	<i>unreported</i>	N	N	0.73	0.40	trace	consistent
6v1,14b,15,17,18	<i>unreported</i>	N	N	0.65	0.37	trace	consistent
6v1,14a,15,18	<i>unreported</i>	N	0.30	N	0.30	trace	consistent
6v1,14b,15,18	<i>unreported</i>	N	0.08	N	N	trace	consistent
6v2,14b,17,18	<i>unreported</i>	N	0.04	N	N	trace	consistent
6v1,14a,16,18	<i>unreported</i>	N	N	N	0.17	trace	consistent
6v2,14b,15,17,18	<i>unreported</i>	N	N	N	0.07	trace	consistent

Table S13. Detected CaMKII δ splice variants

CaMKII δ					
Donor 1					
Replicate 1			Replicate 2		
Variant	Read count	% mapped	Variant	Read count	% mapped
6v1,14b,18	45214	53.1	6v1,14b,18	12388	44.7
6v1,14a,18	24712	29.0	6v1,14a,18	9310	33.6
6v1,14a,16,17,18	6483	7.62	6v1,14a,16,17,18	3204	11.6
6v2,14b,18	4001	4.70	6v1,14a,17,18	957	3.45
6v2,14a,18	1225	1.44	6v1,14b,17,18	393	1.42
6v1,14a,17,18	1121	1.32	6v1,14a	341	1.23
6v1,14b,17,18	820	0.96	6v2,14a,18	289	1.04
6v2,14a,17,18	563	0.66	6v2,14b,18	247	0.89
6v1,14b	431	0.51	6v1,14b	209	0.75
6v1,14a	326	0.38	6v1,14b,16,17,18	170	0.61
6v1,14a,15,17,18	90	0.11	6v1,14a,15,18	84	0.30
6v1,14b,16,17,18	84	0.10	6v1,14b,15,18	21	0.08
Total	85070		6v2,14a,17,18	20	0.07
			6v2,14b,17,18	10	0.04
			6v2,14b,16,17,18	9	0.03
			Total	27660	

Table S14. Read counts of CaMKII δ splice variants from Donor 1

CaMKII δ		
Donor 2		
Variant	Read count	% mapped
6v1,14b,18	7318	40.1
6v1,14a,18	3942	21.6
6v1,14a,16,17,18	3788	20.8
6v1,14a,15,17,18	1126	6.18
6v2,14b,18	1047	5.74
6v2,14a,16,17,18	392	2.15
6v2,14a,18	314	1.72
6v2,14a,15,17,18	133	0.73
6v1,14b,15,17,18	118	0.65
6v2,14b,16,17,18	36	0.20
6v1,14b,16,17,18	13	0.07
Total	18227	

Table S15. Read counts of CaMKII δ splice variants from Donor 2

CaMKII δ		
Donor 3		
Variant	Read count	% mapped
6v1,14a,18	5094	33.6
6v1,14b,18	3993	26.4
6v1,14a,16,17,18	2360	15.6
6v1,14a,17,18	1443	9.53
6v2,14a,16,17,18	493	3.26
6v2,14b,18	433	2.86
6v1,14a,15,17,18	356	2.35
6v1,14b,17,18	192	1.27
6v2,14a,17,18	190	1.26
6v2,14a,18	180	1.19
6v1,14b,16,17,18	165	1.09
6v2,14a,15,17,18	61	0.40
6v1,14b,15,17,18	56	0.37
6v1,14a,15,18	45	0.30
6v1,14a,16,18	25	0.17
6v2,14b,16,17,18	11	0.07
6v2,14b,15,17,18	11	0.07
Total	15108	

Table S16. Read counts of CaMKII δ splice variants from Donor 3

CaMKII β			
Pearson correlation			
	Donor 1, R2	Donor 2	Donor 3
Donor 1, R1	0.963	0.923	0.965
Donor 1, R2		0.982	0.968
Donor 2			0.935
Spearman rank-based correlation			
	Donor 1, R2	Donor 2	Donor 3
Donor 1, R1	0.845	0.619	0.848
Donor 1, R2		0.912	0.823
Donor 2			0.666

Table S17. Pearson and Spearman correlation matrices for CaMKII β variants

CaMKII γ			
Pearson correlation			
	Donor 1, R2	Donor 2	Donor 3
Donor 1, R1	0.913	0.771	0.498
Donor 1, R2		0.939	0.673
Donor 2			0.535
Spearman rank-based correlation			
	Donor 1, R2	Donor 2	Donor 3
Donor 1, R1	0.870	0.608	0.733
Donor 1, R2		0.891	0.874
Donor 2			0.767

Table S18. Pearson and Spearman correlation matrices for CaMKII γ variants

CaMKII δ			
Pearson correlation			
	Donor 1, R2	Donor 2	Donor 3
Donor 1, R1	0.974	0.927	0.823
Donor 1, R2		0.932	0.924
Donor 2			0.841
Spearman rank-based correlation			
	Donor 1, R2	Donor 2	Donor 3
Donor 1, R1	0.855	0.965	0.846
Donor 1, R2		0.931	0.912
Donor 2			0.949

Table S19. Pearson and Spearman correlation matrices for CaMKII δ variants

File S1. Exon sequences for all CaMKII genes

Italicized nucleotides indicate optionally excluded portions of exons

CaMKII α exons sequences

>Exon 1 (coding part only)

ATGGCCACCATCACCTGCACCCGCTTCACGGAAGAGTACCAGCTCTTCGAGGAATTGGGCAA

>Exon 2

GGGAGCCTTCTCGGTGGTGCGAAGGTGTGTGAAGGTGCTGGCTGGCCAGGAGTATGCTGCCAAG
ATCATCAACACAAAGAAGCTGTCAGCCAGAG

>Exon 3

ACCATCAGAAGCTGGAGCGTGAAGCCCGCATCTGCCGCCTGCTGAAGCACCCCAACATCG

>Exon 4

TCCGACTACATGACAGCATCTCAGAGGAGGGACACCACTACCTGATCTTCGACCT

>Exon 5

GGTCACTGGTGGGGAAGTGTGTTGAAGATATCGTGGCCCGGGAGTATTACAGTGAGGCGGATGCC
AG

>Exon 6

TCACTGTATCCAGCAGATCCTGGAGGCTGTGCTGCACTGCCACCAGATGGGGGTGGTGCACCGGG
ACCTGAAG

>Exon 7

CCTGAGAATCTGTTGCTGGCCTCCAAGCTCAAGGGTGCCGCAGTGAAGCTGGCAGACTTTGGCCT
GGCCATAGAGGTGGAGGGGGAGCAGCAGGCATGGTTTG

>Exon 8

GGTTTGCAGGGACTCCTGGATATCTCTCCCCAGAAGTGCTGCCGAAGGACCCGTACGGGAAGCCT
GTGGACCTGTGGGCTTGTG

>Exon 9

GGGTCATCCTGTACATCCTGCTGGTTGGGTACCCCCGTTCTGGGATGAGGACCAGCACCGCCTG
TACCAGCAGATCAAAGCCGGCGCCTATGAT

>Exon 10

TTCCCATCGCCGGAATGGGACACTGTCACCCCGGAAGCCAAGGATCTGATCAATAAGATGCTGAC
CATTAAACCATCCAAACGCATCACAGCTGCCGAAGCCCTTAAGCACCCCTGGATCTCG

>Exon 11

CACCGCTCCACCGTGGCATCCTGCATGCACAGACAGGAGACCGTGGACTGCCTGAAGAAGTTCAA
TGCCAGGAGGAAACTGAAG

>Exon 12

GGAGCCATTCTCACCACGATGCTGGCCACCAGGAACCTTCTCCG

>Exon 14

GAGGGAAGAGTGGGGGAAACAAGAAGAGCGATGGTGTGAA

>Exon 15

GAAAAGAAAGTCCAGTTCAGCGTTCAGTTAAT

>Exon 18

GGAATCCTCAGAGAGACCAACACCACCATCGAGGATGAAGACACCAAAG

>Exon 22

TGCGGAAACAGGAAATTATAAAAGTGACAGAGCAGCTGATTGAAGCCATAAGCAATGGAGATTT
TGAGTCCTACAC

>Exon 23

GAAGATGTGCGACCCTGGCATGACAGCCTTCGAACCTGAGGCCCTGGGGAACCTGGTTGAGGGCC
TGGACTTCCATCGATTCTATTTTAAAAACC

>Exon 24

TGTGGTCCCGGAACAGCAAGCCCGTGCACACCACCATCCTGAATCCCCACATCCACCTGATGGGC
GACGAGTCAGCCTGCATCGCCTACATCCGCATCACGCAGTACCTGGACGCTGGCGGCATCCCACG
CACCGCCAGTCGGAGGAGACCCGTGTCTGGCACCGCCGGGATGGCAAATGGCAGATCGTCCACT
TCCACAGATCTGGGGCGCCCTCCGTCCTGCCCCA

>Exon 25 (coding part only)

CTGA

CaMKII β exon sequences

>Exon 1 (coding part only)

ATGGCCACCACGGTGACCTGCACCCGCTTCACCGACGAGTACCAGCTCTACGAGGATATTGGCAA

>Exon 2

GGGGGCTTTCTCTGTGGTCCGACGCTGTGTCAAGCTCTGCACCGGCCATGAGTATGCAGCCAAGA
TCATCAACACCAAGAAGCTGTCAGCCAGAG

>Exon 3

ATCACCAGAAGCTGGAGAGAGAGGCTCGGATCTGCCGCCTTCTGAAGCATTCCAACATCG

>Exon 4

TGCGTCTCCACGACAGCATCTCCGAGGAGGGCTTCCACTACCTGGTCTTCGATCT

>Exon 5

GGTCACTGGTGGGAGCTCTTTGAAGACATTGTGGCGAGAGAGTACTACAGCGAGGCTGATGCC
AG

>Exon 6

TCACTGTATCCAGCAGATCCTGGAGGCCGTTCTCCATTGTCACCAAATGGGGGTCGTCCACAGAG
ACCTCAAG

>Exon 7

CCGGAGAACCTGCTTCTGGCCAGCAAGTGCAAAGGGGCTGCAGTGAAGCTGGCAGACTTCGGCCT
AGCTATCGAGGTGCAGGGGGACCAGCAGGCATGGTTTG

>Exon 8

GTTTCGCTGGCACACCAGGCTACCTGTCCCCTGAGGTCCTTCGCAAAGAGGCGTATGGCAAGCCT
GTGGACATCTGGGCATGTG

>Exon 9

GGGTGATCCTGTACATCCTGCTCGTGGGCTACCCACCCTTCTGGGACGAGGACCAGCACAAGCTG
TACCAGCAGATCAAGGCTGGTGCCTATGAC

>Exon 10

TTCCCCTCCCCTGAGTGGGACACCGTCACTCCTGAAGCCAAAAACCTCATCAACCAGATGCTGAC
CATCAACCCTGCCAAGCGCATCACAGCCCATGAGGCCCTGAAGCACCCGTGGGTCTGC

>Exon 11

CAACGCTCCACGGTAGCATCCATGATGCACAGACAGGAGACTGTGGAGTGTCTGAAAAAGTTCA
ATGCCAGGAGAAAGCTCAAG

>Exon 12

GGAGCCATCCTCACCACCATGCTGGCCACACGGAATTTCTCAG

>Exon 13

TGGGCAGACAGACCACCGCTCCGGCCACAATGTCCACCGCGGCCTCCGGCACCACCATGGGGCTG
GTGGAACAAG

>Exon 14

CAGCCAAGAGTTTACTCAACAAGAAAGCAGATGGAGTCAAG

>Exon 16

CCCCAGACGAATAGCACCAAAAACAGTGCAGCCGCCACCAGCCCCAAAGGGACGCTTCTCCTGC
CGCCCTG

>Exon 17

GAGCCTCAAACCACCGTCATCCATAACCCAGTGGACGGGATTAAG

>Exon 18

GAGTCTTCTGACAGTGCCAATACCACCATAGAGGATGAAGACGCTAAAG

>Exon 19

CCCCAGGGTCCCCGACATCCTGAGCTCAGTGAGGAGGGGCTCGGGAGCCCCAGAAGCCGAGGGG
CCCCTGCCCTGCCATCTCCGGCTCCCTTTAGCCCCCTGCCAGCCCCAT

>Exon 20

CCCCAGGATCTCTGACATCCTGAACTCTGTGAGAAGGGGTTTCCAGGAACCCCAGAAGCCGAGGGC
CCCCTCTCAGCGGGCCCCCGCCCTGCCTGTCTCCGGCTCTCCTAGGCCCCCTGTCTCCCCGT

>Exon 21

CCCCAGGATCTCTGACATCCTGAACTCTGTGAGGAGGGGCTCAGGGACCCCAGAAGCCGAGGGC
CCCTCGCCAGTGGGGCCCCCGCCCTGCCATCTCCGACTATCCCTGGCCCCCTGCCACCCCCAT

>Exon 22

CCCGAAGCAGGAGATCATTAAAGACCACGGAGCAGCTCATCGAGGCCGTCAACAACGGTGACTTT
GAGGCCTACGC

>Exon 23

GAAAATCTGTGACCCAGGGCTGACCTCGTTTGGCCTGAAGCACTGGGCAACCTGGTTGAAGGGATGG
ACTTCCACAGATTCTACTTCGAGAACC

>Exon 24

TGCTGGCCAAGAACAGCAAGCCGATCCACACGACCATCCTGAACCCACACGTGCACGTCAATTGGA
GAGGATGCCGCTGCATCGCTTACATCCGGCTCACGCAGTACATTGACGGGCAGGGCCGGCCCCG
CACCAGCCAGTCTGAGGAGACCCGCGTGTGGCACCCGCGACGGCAAGTGGCAGAACGTGCACT
TCCACTGCTCGGGCGCGCCTGTGGCCCCGCTGCAGTGA

CaMKII γ exon sequences

>Exon 1 (coding part only)

ATGGCCACCACCGCCACCTGCACCCGTTTCACCGACGACTACCAGCTCTTCGAGGAGCTTGGCAA

>Exon 2

GGGTGCTTTCTCTGTGGTCCGCAGGTGTGTGAAGAAAACCTCCACGCAGGAGTACGCAGCAAAAA
TCATCAATACCAAGAAGTTGTCTGCCCGG

>Exon 3

ATCACCAGAACTAGAACGTGAGGCTCGGATATGTGACTTCTGAAACATCCAAACATCG

>Exon 4

TGCGCCTCCATGACAGTATTTCTGAAGAAGGGTTTCACTACCTCGTGTTTGACCT

>Exon 5

TGTTACCGGCGGGGAGCTGTTTGAAGACATTGTGGCCAGAGAGTACTACAGTGAAGCAGATGCC
AG

>Exon 6

CCACTGTATACATCAGATTCTGGAGAGTGTTAACCACATCCACCAGCATGACATCGTCCACAGGG
ACCTGAAG

>Exon 7

CCTGAGAACCTGCTGCTGGCGAGTAAATGCAAGGGTGCCGCCGTCAAGCTGGCTGATTTTGGCCT
AGCCATCGAAGTACAGGGAGAGCAGCAGGCTTGGTTTG

>Exon 8

GTTTTGCTGGCACCCCAGGTTACTTGTCCCCTGAGGTCTTGAGGAAAGATCCCTATGGAAAACCT
GTGGATATCTGGGCCTGCG

>Exon 9

GGGTCATCCTGTATATCCTCCTGGTGGGCTATCCTCCCTTCTGGGATGAGGATCAGCACAAGCTG
TATCAGCAGATCAAGGCTGGAGCCTATGAT

>Exon 10

TTCCCATCACCAGAATGGGACACGGTAACTCCTGAAGCCAAGAAGTTGATCAACCAGATGCTGAC
CATAAACCCAGCAAAGGCGATCACGGCTGACCAGGCTCTCAAGCACCCGTGGGTCTGT

>Exon 11

CAACGATCCACGGTGGCATCCATGATGCATCGTCAGGAGACTGTGGAGTGTTTGCGCAAGTTCAA
TGCCCGGAGAAAACCTGAAG

>Exon 12

GGTGCCATCCTCACGACCATGCTTGTCTCCAGGAACTTCTCAG

>Exon 13

TTGGCAGGCAGAGCTCCGCCCCCGCCTCGCCTGCCGCGAGCGCCGCCGGCCTGGCCGGGCAAG

>Exon 14

CTGCCAAAAGCCTATTGAACAAGAAGTCGGATGGCGGTGTCAAG

>Exon 15

AAAAGGAAGTCGAGTTCCAGCGTGCACCTAATG

>Exon 16

CCACAGAGCAACAACAAAAACAGTCTCGTAAGCCCAGCCCAAGAGCCCGGCCCTTGCAGACGGC
CATG

>Exon 17

GAGCCACAAACCACTGTGGTACACAACGCTACAGATGGGATCAAG

>Exon 18

GGCTCCACAGAGAGCTGCAACACCACCACAGAAGATGAGGACCTCAAAGGTAG

>Exon 19

CTGCCCCGCTCCGCACTGGGAATGGCAGCTCGGTGCCTGAAGGACGGAGCTCCCGGGACAGAACAG
CCCCCTCTGCAGGCATGCAGCCCCAGCCTTCTCTCTGCTCCTCAGCCA

>Exon 22

TGCGAAAACAGGAGATCATTAAGATTACAGAACAGCTGATTGAAGCCATCAACAATGGGGACTT
TGAGGCCTACAC

>Exon 23

GAAGATTTGTGATCCAGGCCTCACTTCCCTTTGAGCCTGAGGCCCTTGGTAACCTCGTGGAGGGGA
TGGATTTCCATAAGTTTTACTTTGAGAATC

>Exon 24 (coding part only)

TCCTGTCCAAGAACAGCAAGCCTATCCATACCACCATCCTAAACCCACACGTCCACGTGATTGGG
GAGGACGCAGCGTGCATCGCCTACATCCGCCTCACCCAGTACATCGACGGGCAGGGTCGGCCTCG
CACCAGCCAGTCAGAAGAGACCCGGGTCTGGCACCGTCGGGATGGCAAGTGGCTCAATGTCCACT
ATCACTGCTCAGGGGCCCTGCCGCACCGCTGCAGTGA

CaMKII δ exon sequences

>Exon 1 (coding part only)

ATGGCTTCGACCACAACCTGCACCAGGTTACGGACGAGTATCAGCTTTTCGAGGAGCTTGGAAA

>Exon 2

GGGGGCATTCTCAGTGGTGAGAAGATGTATGAAAATTCCTACTGGACAAGAATATGCTGCCAAA
ATTATCAACACCAAAAAGCTTTCTGCTAGGG

>Exon 3

ATCATCAGAACTAGAAAGAGAAGCTAGAATCTGCCGTCTTTTGAAGCACCTAATATTG

>Exon 4

TGCGACTTCATGATAGCATATCAGAAGAGGGCTTTCCTACTTGGTGTTTGATT

>Exon 5

AGTTACTGGAGGTGAACTGTTTGAAGACATAGTGGCAAGAGAATACTACAGTGAAGCTGATGCC
AG

>Exon 6v1

TCATTGTATACAGCAGATTCTAGAAAGTGTTAATCATTGTCACCTAAATGGCATAGTTCACAGG
GACCTGAAG

>Exon 6v2

TCATTGCATTCAGCAGATCCTGGAGGCTGTGCTACACTGCCATCAGATGGGCGTGGTCCATCGGG
ACCTGAAG

>Exon 7

CCTGAGAATTTGCTTTTAGCTAGCAAATCCAAGGGAGCAGCTGTGAAATTGGCAGACTTTGGCTT
AGCCATAGAAGTTCAAGGGGACCAGCAGGCGTGGTTTG

>Exon 8

GTTTTGCTGGCACACCTGGATATCTTTCTCCAGAAGTTTTACGTAAAGATCCTTATGGAAAGCCA
GTGGATATGTGGGCATGTG

>Exon 9

GTGTCATTCTCTATATTCTACTTGTGGGGTATCCACCCTTCTGGGATGAAGACCAACACAGACTC
TATCAGCAGATCAAGGCTGGAGCTTATGAT

>Exon 10

TTTCCATCACCAGAATGGGACACGGTGACTCCTGAAGCCAAAGACCTCATCAATAAAATGCTTAC
TATCAACCCTGCCAAACGCATCACAGCCTCAGAGGCACTGAAGCACCCATGGATCTGT

>Exon 11

CAACGTTCTACTGTTGCTTCCATGATGCACAGACAGGAGACTGTAGACTGCTTGAAGAAATTTAA
TGCTAGAAGAAAATAAAG

>Exon 12

GGTGCCATCTTGACAACCTATGCTGGCTACAAGGAATTTCTCAG

>Exon 14

CAGCCAAGAGTTTGTGAAGAAACCAGATGGAGTAAAG

>Exon 15

AAAAGGAAGTCCAGTTCGAGTGTTTCAGATGATG

>Exon 16

ATAAACAAACAAAGCCAACGTGGTAACCAGCCCCAAAGAAAATATTCCTACCCCAGCGCTG

>Exon 17

GAGCCCCAAACTACTGTAATCCACAACCCTGATGGAAACAAG

>Exon 18

GAGTCAACTGAGAGTTCAAATACAACAATTGAGGATGAAGATGTGAAAG

>Exon 22

CACGAAAGCAAGAGATTATCAAAGTCACTGAACAACCTGATCGAAGCTATCAACAATGGGGACTT
TGAAGCCTACAC

>Exon 23

AAAAATCTGTGACCCAGGCCTTACTGCTTTTGAACCTGAAGCTTTGGGTAATTTAGTGGAAGGG
ATGGATTTTCACCGATTCTACTTTGAAAATG

>Exon 24

CTTTGTCCAAAAGCAATAAACCAATCCACACTATTATTCTAAACCCTCATGTACATCTGGTAGGG
GATGATGCCGCTGCATAGCATATATTAGGCTCACACAGTACATGGATGGCAGTGGAATGCCAA
AGACAATGCAGTCAGAAGAGACTCGTGTGTGGCACC GCCGGGATGGAAAGTGGCAGAATGTTCA
TTTTCATCGCTCGGGGTCACCAACAGTACCCATCAA

>Exon 25 (coding part only)

GCCACCCTGTATTCCAAATGGGAAAGAAAACCTTCTCAGGAGGCACCTCTTTGTGGCAAAACATCT
AA

>Exon 26 (coding part only)

GTAA

File S2. Primers for initial amplification of variably spliced transcript regions

CaMKII α

F: CCTGGATCTCGCACCGCTCCACCGT

R: GGCTGTCATGCCAGGGTCGCACATCTTCG

CaMKII β

F: CCTGAGGTCCTTCGCAAAGAGGGCGTATGGC

R: GCAGGCGGCATCCTCTCCAATGACGTGC

CaMKII γ

F: GCGCATCACGGCTGACCAGGCTCTCA

R: CCATCCCCTCCACGAGGTTACCAAGGGCC

CaMKII δ

F: GCTTGAAAGGGGGCATTCTCAGTGGTGAGAAGATG

R: TGCAGGCGGCATCATCCCCTACCAGATGTACA

Gene-specific primers for Illumina sequencing library construction:

CaMKII α

F: CATCCTCACCACCATGCTG

R: CCAGCAGGTTCTCGAAGTAG

CaMKII β

F: TGGATCTCGCACCGCT

R: GTCGCACATCTTCGTGTAGG

CaMKII γ

F: CCTCACGACCATGCTTGTCT

R: CCCCTCCACGAGGTTACC

CaMKII δ

F: CAGTGAAGCTGATGCCAGTC

R: TG TTCAGTGACTTTGATAATCTCTTGC

Library construction primers contain the following generic 3' overhangs

F: A CACTCTTTCCCTACACGACGCTCTTCCGATCT

R: CTGGAGTTCAGACGTGTGCTCTTCCGATC